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ABSTRACT	OF	THE	DISSERTATION		Synthesis	of	α-L-Threofuranosyl	Nucleosides,	Phosphoramidites,	and	Triphosphates	for	Synthetic	Biology		By		Saikat	Bala		Doctor	of	Philosophy	in	Pharmaceutical	Sciences			University	of	California,	Irvine,	2019		Professor	John	C	Chaput,	Chair		 	A	major	goal	of	synthetic	biology	is	to	recapitulate	emergent	properties	of	life.	Despite	a	significant	body	of	work,	a	longstanding	question	that	remains	to	be	answered	is	how	such	a	 complex	 system	 arose?	 In	 this	 dissertation,	 synthetic	 nucleic	 acid	 molecules	 with	alternative	sugar-phosphate	backbones	were	investigated	as	potential	ancestors	of	DNA	and	RNA.	 Threose	 nucleic	 acid	 (TNA)	 is	 capable	 of	 forming	 stable	 duplex	 structure	 with	complementary	strands	of	itself	and	RNA.	This	provides	a	plausible	mechanism	for	genetic	information	 transfer	 between	 TNA	 and	 RNA.	 Therefore	 TNA	 has	 been	 proposed	 as	 a	potential	RNA	progenitor.	Using	molecular	 evolution,	 functional	 sequences	were	 isolated	from	 a	 pool	 of	 random	 TNA	 molecules.	 This	 implicates	 a	 possible	 chemical	 framework	capable	of	crosstalk	between	TNA	and	RNA.	Further,	this	shows	that	heredity	and	evolution	are	 not	 limited	 to	 the	 natural	 genetic	 system	 based	 on	 ribofuranosyl	 nucleic	 acids.	Structurally	different	from	DNA	and	RNA,	TNA	was	further	explored	as	a	source	of	nuclease	
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resistant	 affinity	 reagents	 in	 therapeutic	 application.	 Since	 TNA	molecules	 are	 naturally	unavailable,	 synthetic	 approach	 has	 been	 developed	 previously	 for	 initial	 research	explorations.	A	detailed	synthetic	optimization	have	been	investigated	in	this	dissertation	to	provide	quantitative	amount	of	TNA	substrates	for	the	downstream	research	applications	in	Synthetic	biology.		Chapter	2	describes	a	highly	optimized	synthetic	approach	for	large	scale	preparation	of	α-L-threose	nucleoside	and	phosphoramidites	by	ten	reaction	steps	form	L-ascorbic	acid.	This	new	strategy	overcomes	several	shortcomings	from	original	method	presented	by	Dr.	Eschenmoser	 and	 co-workers	 and	 allow	 us	 to	 quantitatively	 synthesize	 several	 key	intermediate	precursors	 for	 the	α-L-threose	nucleoside	phosphoramidites	and	nucleoside	triphosphate	synthesis.	The	α-L-threose	nucleoside	phosphoramidites	are	then	used	as	the	monomers	for	the	synthesis	of	TNA	oligonucleotides	by	solid	phase	chemistry.	Chapter	 3	 discusses	 the	 stepwise	 approach	 of	 development	 for	 synthesizing	 α-L-threose	nucleoside	3’-monophosphate	and	3’-triphosphate.	3’-Secondary	hydroxyl	group	on	α-L-threose,	having	steric	encumbered	issue	from	the	neighboring	nucleobases,	presents	the	low	efficiency	in	the	phosphorylation	step	by	using	classic	P(V)	chemistry.	Introducing	P(III)	phosphitylation,	 substitution,	 and	 subsequent	 oxidation	 reaction	 together	 achieve	 high	phosphorylation	 yield	 on	 3’-hydroxyl	 group	 of	 α-L-threose	 nucleoside	 and	 facilitate	 α-L-threose	 nucleoside	 3’-monophosphate	 and	 3’-triphosphate	 synthesis	 and	 purification	 by	HPLC	 chromatography.	 The	 α-L-threose	 nucleoside	 3’-triphosphates	 are	 tested	 as	 the	substrates	for	enzymatic	TNA	oligonucleotide	synthesis	by	engineered	polymerases.	Chapter	 4	 discusses	 the	 synthesis	 of	 2’-deoxy-α-L-threose	 nucleoside	 using	 two	deoxygenation	 approaches.	 Introducing	 the	 triethylborane	 as	 the	 radical	 initiator,	 that	
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Figure	1.4	Comparative	nuclease	stability	assays	performed	in	human	serum	(HS)	and	human	liver	microsomes	(HLM).	(a)	TNA	polymers	remain	undigested	after	7	days	of	incubation	at	37°C	in	50%	human	serum	or	0.5	mg/mL	human	liver	microsomes.	Buf	denotes	buffer	only.	(b)	FANA	and	2’-F-RNA	both	rapidly	degrade	under	simulated	biological	conditions.	(c)	Chemical	structure	of	FANA	and	2’-F-RNA.			(Figure	was	used	with	permission	from	Bioorg.	Med.	Chem.	Lett,	2016,26,	2418-2421)			TNA	 is	 an	 unnatural	 nucleic	 acid	 that	 is	 not	 commercially	 available.	 Thus,	 we	synthesize	 TNA	monomers	 and	 polymers	 chemically	 in	 lab.	 All	 the	monomers	 shown	 in	figure	 4	 are	 used	 for	 all	 the	projects	 in	 our	 lab.	 The	 top	 row	 corresponds	 to	 the	TNA-2-phosphoramidite	 with	 3'	–O-DMT	 protection	 (tN-amidites,	 N	 =	 A,T,G,C).	 These	 listed	
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Most	 of	 the	 commercial	 sources	 obtain	 their	 nucleoside	 triphosphates	 (NTPs)	 via	
biocatalytic	 methods.	 These	 methods	 are	 extremely	 useful	 for	 the	 synthesis	 of	 natural	triphosphates	 (A,	 C,	 G,	 and	T).	 Such	 is	made	 possible	 by	 the	 enzymatic	 extraction	 of	 the	desired	product	from	their	natural	sources.	It	is	observed	that	adenosine	may	be	converted	into	ATP	using	a	mixture	of	three	enzymes:	adenosine	kinase,	adenylate	kinase,	and	acetate	kinase.40	 Similarly,	 deoxyribonucleic	 triphosphates	 may	 be	 extracted	 from	 the	corresponding	ribonucleotide	counterpart	with	ribonucleotide	reductase	(Scheme	1.3).								
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2.1 Contribution Statement 
 Fahmi,	N.	E.	and	Sau,	S.	P.	designed	the	synthetic	strategy.	All	authors	contributed	to	the	synthesis,	reaction	optimization,	and	data	collection.	Sau,	S.	P.	and	Chaput,	 J.	C.	wrote	the	manuscript	with	the	comments	from	the	rest	of	the	authors.	
2.2 Abstract of the Chapter 
 Recent	advances	in	polymerase	engineering	have	made	it	possible	to	copy	information	back	 and	 forth	 between	 DNA	 and	 artificial	 genetic	 polymers	 composed	 of	 TNA	 (α	 -L	 -threofuranosyl-	(3′	,2′	)	nucleic	acid).	This	property,	coupled	with	enhanced	nuclease	stability	relative	to	natural	DNA	and	RNA,	warrants	further	investigation	into	the	structural	and	functional	properties	of	TNA	as	an	artificial	genetic	polymer	for	synthetic	biology.	Here,	we	 report	 a	 highly	 optimized	 chemical	 synthesis	 protocol	 for	 constructing	 multigram	quantities	 of	 TNA	 nucleosides	 that	 can	 be	 readily	 converted	 to	 nucleoside	 2′	 -
17		
phosphoramidites	or	3′	-	triphosphates	for	solid-phase	and	polymerase-mediated	synthesis,	respectively.	 The	 synthetic	 protocol	 involves	 10	 chemical	 transformations	 with	 three	crystallization	steps	and	a	single	chromatographic	purification,	which	results	in	an	overall	yield	of	16−	23%	depending	on	the	identity	of	the	nucleoside	(A,	C,	G,	T).	
2.3 Introduction 
 TNA	(α-L-threofuranosyl-(3′,2′)-nucleic	acid)	is	an	artificial	genetic	polymer	in	which	the	natural	ribose	sugar	found	in	RNA	has	been	replaced	by	the	α-L-threose	sugar.	In	contrast	to	natural	 DNA	 and	RNA,	which	 have	 a	 six-atom	backbone	 repeat	 unit	 connected	 by	 3′,	 5′-phosphodiester	 linkages,	 TNA	 has	 five	 atoms	 (or	 covalent	 bonds)	 in	 the	 phosphodiester	backbone	with	 linkages	 occurring	 at	 the	 2′	 and	 3′	 vicinal	 positions	 of	 the	 threose	 sugar.	Despite	 this	major	difference	 in	 structure,	TNA	 is	 capable	 of	 forming	 stable	 and	 efficient	antiparallel	Watson−Crick	duplexes	with	complementary	strands	of	DNA	and	RNA.	1−3	The	ability	 to	 transfer	genetic	 information	between	TNA	and	RNA,	coupled	with	 the	chemical	simplicity	 of	 threose	 relative	 to	 ribose	 sugar,	 has	 fueled	 interest	 in	 TNA	 as	 a	 possible	progenitor	 of	 RNA	 in	 the	 pre-RNA	world	 hypothesis.4−6	 TNA	 is	 also	 being	 explored	 as	 a	catalysts	for	synthetic	biology,	source	of	nuclease	resistant	reagents,	and	molecular	affinity	medicine	 for	 biological	 targets,	 as	 the	 constitutional	 structure	 of	 TNA	 is	 stable	 under	biological	 conditions.	Ongoing	works	 in	both	of	 these	 areas	have	 inspired	 researchers	 to	develop	 the	 engineered	 polymerases	 that	 can	 “transcribe”	 DNA	 into	 TNA	 and	 other	polymerases	that	can	“reverse	transcribe”	TNA	back	into	DNA.7−12	By	including	a	selective	amplification	 step	 in	 the	 replication	 cycle,	 methods	 are	 now	 being	 developed	 to	 isolate	functional	TNA	molecules	by	in	vitro	selection.13	
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nucleoside	 precursors	 that	 can	 be	 readily	 converted	 to	 3′-triphosphates	 for	 polymerase-mediated	primer-extension	reactions	or	2’-phosphoramidites	for	solid-phase	synthesis.	Our	approach	 involves	a	 total	of	10	chemical	 transformations	with	 three	crystallization	and	a	single	 chromatographic	 purification	 steps	 and	 results	 in	 an	 overall	 yield	 of	 16−23%	depending	 on	 the	 identity	 of	 the	 nucleoside	 (A,	 C,	 G,	 T).	We	 demonstrate	 that	 this	 new	strategy	can	be	used	to	produce	multigram	quantities	of	TNA	monomers	for	the	downstream	exploration	in	structural	and	functional	properties	of	TNA	polymers.	
2.4	Results	and	Discussion	
 The	 synthesis	 of	 L-threonolactone	 (2.2)	 from	 L-ascorbic	 acid	 (vitamin	 C)	 has	 been	reported	 previously	 (Scheme	 2-1).	 Accordingly,	 L-ascorbic	 acid	 undergoes	 oxidative	cleavage	in	the	presence	of	hydrogen	peroxide	and	CaCO3	to	produce	the	calcium	salt	of	L-threonate	(2.6).	Compound	2.6	is	then	converted	to	the	desired	L-threonolactone	(2.2)	using	a	Dowex	cation	exchange	resin	 to	promote	acidification	and	 intramolecular	 lactonization.	However,	due	to	the	limited	solubility	of	2.6,	both	steps	require	to	remove	the	large	volumes	of	water	prior	to	cyclization	and	crystallization.	We	began	by	examining	 the	crystallization	of	2.6	 from	the	resulting	aqueous	reaction	mixture.	 Literature	 methods	 report	 to	 reduce	 the	 volume	 of	 the	 aqueous	 solution	 by	diminished-pressure	evaporation	prior	to	crystallization	with	methanol;	however,	this	is	a	tedious	process,	especially	when	the	reaction	is	performed	on	a	large	scale.	We	found	that	the	addition	of	2	volumetric	equivalents	of	methanol	directly	to	the	reaction	mixture	allowed	
2.6	 to	precipitate	 as	 a	white	 crystalline	material	 in	85%	yield.	 This	 subtle	 change	 to	 the	
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required	 to	 synthesize	 TNA	 3′-nucleoside	 triphosphates,	 a	 cumbersome	 strategy	 of	protection	and	deprotection	was	developed	to	convert	2.5a	into	2.5b.14	In	an	effort	to	generate	antiviral	compounds	based	on	the	structural	framework	of	TNA	nucleosides,	Herdewijn	and	colleagues	developed	a	regioselective	strategy	that	defined	the	2′	 	 and	 3′	 	 hydroxyl	 positions	 early	 in	 the	 synthetic	 pathway.	 Accordingly,	 the	 authors	reported	that	2	 	could	be	selectively	converted	2.2	 to	 the	2-O	-benzoyl	L	 -threonolactone	derivative	1.7	 by	 the	 addition	 of	 benzoyl	 chloride	 to	 a	 solution	 of	2.2	 	 and	 imidazole	 in	acetonitrile	after	8	h	of	stirring	from	−	5	°	C	to	room	temperature	(Scheme	2-2).	Although	this	method	proved	unsatisfactory	in	our	hands,	selective	benzoylation	of	2.2		was	achieved	with	the	addition	of	1	equiv.	of	benzoyl	chloride	to	2.2		in	1:10	pyridine−	dichloromethane	solution	after	stirring	for	30	min	at	0	°	C.	Following	the	reaction,	we	further	discovered	that	
2.7		could	be	precipitated	as	a	pure	white	powder	in	64%	yield	after	stirring	overnight	at	4	°	C	from	a	mixture	of	dichloromethane	and	hexanes.	In	 analogy	 to	 previous	 work	 on	 threofuranosyl	 nucleosides,2.8	 compound	 2.7	 was	converted	 to	 the	 universal	 glycosyl	 donor	 2.8	 following	 three	 successive	 chemical	transformations.	 We	 introduced	 the	 tert-butyldiphenylchlorosilyl	 protection	 at	 the	 3’-hydroxy	 position	 of	2.7,	 followed	 by	DIBAL-H	 reduction	 of	 the	 lactone	 to	 the	 lactol,	 and	finally	acetylation	at	the	anomeric	position	to	give	2.8	in	96%	yield	from	2.7.	Filtration	of	
2.8	 through	 a	 short-pad	 of	 silica	 gel	 proved	 highly	 facile	 and	 efficient	 due	 to	 the	 strong	polarity	differences	between	2.8	and	the	nonwashable	reagents.	From	2.8,	we	constructed	a	complete	set	of	TNA	nucleosides	for	thymidine	(T,	2.9c),	cytidine	(C,	2.9b),	adenosine	(A,	
2.9a),	and	guanosine	(G,	2.9d)	by	applying	a	Vorbrüggen	glycosylation	(Scheme	2-3)	that	involved	heating	the	nucleobase	(in	protected	form)	with	glycosyl	donor	in	the	presence	of	
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AgOTf	as	the	catalyst.	Removal	of	the	O6-diphenylcarbamoyl	(DPC)	group	with	20%	TFA	in	CH2Cl2	allowed	tritylation	to	occur	under	standard	conditions,	suggesting	that	the	bulky	DPC	group	creates	the	steric	barrier	to	limit	the	addition	of	the	DMT	group.	In	 our	 laboratory,	we	 routinely	 synthesize	 TNA	 nucleosides	2.9a−d	using	 the	 above-mentioned	methodology.	In	a	typical	synthesis	run,	125	g	of	2.1	is	converted	into	80	g	of	2.7	with	 an	 overall	 yield	 of	 49%.	 In	 contrast	 to	 previously	 methods,	 modifications	 to	 the	purification	protocol	of	2.6	and	2.2	makes	it	possible	to	generate	large	quantities	of	highly	pure	2.7	in	just	5	days.	The	conversion	of	2.7	to	2.8	is	generally	performed	with	16.5	g	of	2.7	to	obtain	35	g	of	2.8	with	an	overall	yield	of	96%	in	24	h.	The	N-glycosylation	of	2.8,	followed	by	desilylation,	affords	nucleosides	2.9a−d	 in	64−70%	yield,	with	 the	noted	exception	of	
2.9c,	which	is	obtained	in	slightly	lower	yield	(43.5%).	We	have	found	that	the	synthesis	of	
2.9a−d	 from	 2.7	 can	 be	 performed	 on	 scales	 as	 large	 as	 50	 g,	 which	 is	 a	 substantial	improvement	 in	 the	 synthesis	 of	 TNA	 nucleoside	molecules	 that	will	 help	 accelerate	 the	synthesis	and	characterization	of	TNA	polymers.	
	
2.5	Conclusion	
 In	summary,	we	provide	a	scalable	and	optimized	synthesis	protocol	for	constructing	L-threofuranosyl	 nucleosides	 that	 are	 immediate	 precursors	 for	 TNA	 triphosphates	 and	phosphoramidite	 monomers	 synthesis.	 Several	 key	 challenges	 have	 been	 resolved	 and	numbers	of	purification	steps	were	minimized	to	increase	the	yield	of	key	intermediates	and	product	 synthesis.	 The	 conversion	 of	 vitamin	 C	 to	 L-threonolactone	 was	 optimized	 to	minimize	 the	 cost	 and	 for	 generating	 a	 key	 intermediate	 in	 the	 synthesis	 pathway.	 The	
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universal	glycosyl	donor	2.8	was	prepared	 from	2.7	 in	 three	chemical	 steps,	 followed	by	filtration	through	a	short	pad	of	silica	gel.	The	complete	set	of	TNA	nucleosides	(2.9a−d)	were	synthesized	in	two	reactions	from	2.8	and	purified	by	crystallization.	Final	tritylation,	followed	 by	 debenzoylation,	 provided	 the	 desired	 compounds	 (2.10a−d)	 after	 silica	 gel	column	chromatography.	Together,	these	changes	make	it	possible	to	synthesize	multigram-scale	quantities	of	TNA	monomers	that	can	be	used	to	synthesize	TNA	polymers.	
2.6	Experimental	Details	
General	Procedures	





	Calcium-L-threonate	(2.6).15	To	a	cold	(0−5	°C)	solution	containing	125	g	(0.71	mol)	of	L-ascorbic	acid	(2.1)	in	1	L	of	H2O	was	slowly	added	125	g	(1.3	mol)	of	CaCO3	with	a	spatula	over	30	min	(evolution	of	CO2	was	observed).	To	the	resulting	heterogeneous	slurry	was	added	250	mL	of	30%	aq.	H2O2	dropwise	over	a	period	of	ca.	1	h	with	stirring	at	0−5	°C.	The	reaction	mixture	was	allowed	to	warm	to	r.t	and	stirred	overnight.	The	heterogeneous	slurry	was	filtered,	and	the	filter	cake	was	washed	with	two-100	mL	portions	of	H2O.	The	filtrate	was	treated	with	25	g	of	activated	carbon	Darco	G-60	and	then	heated	to	50	°C,	until	peroxide	was	no	longer	detected	using	Merckoquant	1001-1	peroxide	 test	 strips.	The	hot	suspension	was	 filtered,	and	 the	solid	material	was	washed	with	two-50	mL	portions	of	H2O.	The	washings	and	the	filtrate	were	combined	and	crystallized	by	the	addition	of	2	volume	equivalents	of	methanol	while	stirring	for	16	h	at	4	°C.	The	solid	material	was	filtered,	washed	with	two-50	mL	portions	of	MeOH,	and	dried	under	high	vacuum	at	40	°C.	Calcium	L-threonate	monohydrate	(2.6)	was	obtained	as	a	white	solid:	yield	99.4	g	(85%);	1H	NMR	(400	MHz,	D2O)	δ	3.60	(dd,	1H,	J	=	11.6,	7.6	Hz),	3.66	(dd,	1H,	J	=	11.6,	5.2	Hz),	3.95	(m,	1H)	and	4.03	(m,	1H).	
	





1-O-Acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threofuranose	(2.8).18	To	 a	 cold	 (0−5	 °C)	 solution	 containing	 16.5	 g	 (74.3	 mmol)	 of	 2-O-benzoyl-L-threonolactone	 (2.7),	 60	mg	of	DMAP	and	10.2	 g	 (150	mmol)	 of	 imidazole	 in	160	mL	of	CH2Cl2	 was	 added	 dropwise	 tert-butyldiphenylchlorosilane	 (20	 mL,	 75.0	 mmol).	 The	reaction	mixture	was	warmed	 to	 r.t.	 and	 stirred	 under	 argon	 for	 16	 h.	 The	 solvent	was	
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evaporated	under	reduced	pressure,	and	the	residue	was	dissolved	in	300	mL	of	hexane.	The	organic	phase	was	sequentially	washed	with	1	N	HCl	(100	mL),	H2O	(100	mL),	and	brine	(100	mL).	The	organic	layer	was	dried	over	MgSO4	and	evaporated	to	give	2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threonolactone	as	a	colorless	syrup	(35	g).	The	crude	material	was	used	directly	without	further	purification;	silica	gel	TLC	(3:1	hexanes−EtOAc)	Rf	=	0.5.	To	a	cold	(−78	°C,	acetone/dry	ice)	solution	containing	35.0	g	of	crude	2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threonolactone	in	150	mL	of	1,2-dimethoxyethane	was	added	a	1	M	solution	of	DIBAL-H	in	toluene	(100	mL,	100	mmol)	dropwise	over	a	10	min	period.	The	mixture	was	stirred	under	argon	for	an	additional	20	min	at	−78	°C.	TLC	showed	the	reaction	to	be	complete	(Rf	0.35	 in	3:1	hexanes−EtOAc).	A	premade	solution	containing	Ac2O	(367	mmol)	and	DMAP	(115	mmol)	in	CH2Cl2	(Ac2O/DMAP/CH2Cl2	=	35	mL/14.0	g/40	mL)	was	then	added	dropwise	at	−78	°C.	After	10	min,	the	reaction	mixture	was	removed	from	the	dry	ice	bath	and	allowed	to	stir	for	1.5	h	while	warming	to	r.t.	The	mixture	was	then	diluted	with	200	mL	of	hexanes	and	poured	into	a	cold	stirring	1	N	aq.	HCl	solution	(200	mL).	The	organic	layer	was	separated	and	washed	with	H2O	(100	mL),	sat.	aq.	NaHCO3	(100	mL),	and	brine	(100	mL).	The	organic	 layer	was	dried	over	MgSO4	and	evaporated	to	give	 	42	g	of	crude	product	as	a	yellow	syrup.	The	product	was	suspended	 in	25	mL	of	10%	EtOAc	 in	hexanes,	passed	 through	a	short	pad	of	 silica	 (50	g),	and	washed	out	with	10%	EtOAc	 in	hexanes	 (200	 mL).	 An	 anomeric	 mixture	 of	 1-O-acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threo-furanose	 (2.8)	was	 obtained	 as	 a	 colorless	 syrup:	 yield	 36.0	 g	(96%);	silica	gel	TLC	(3:1	hexanes−EtOAc):	Rf	=	0.5.		
1-(2′-O-Benzoyl-α-L-threofuranosyl)thymine	(2.9a).	
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To	 a	 solution	 containing	 34.0	 g	 (67.4	 mmol)	 of	 1-O-acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threofuranose	 (2.8)	 and	8.9	 g	 (70.5	mmol)	 of	 thymine	 in	140	mL	of	anhydrous	acetonitrile	was	added	45	mL	(145	mmol)	of	BSA,	and	the	mixture	was	stirred	for	30	 min	 at	 60	 °C.	 TMSOTf	 (20.0	 mL,	 108	 mmol)	 was	 added	 dropwise,	 and	 stirring	 was	continued	 for	 another	 2	 h	 at	 60	 °C,	 after	 which	 time	 TLC	 analysis	 (1:1	 hexanes−EtOAc)	showed	the	reaction	to	be	complete.	The	mixture	was	cooled	to	r.t,	diluted	with	300	mL	of	EtOAc,	and	poured	into	200	mL	of	cold	sat.	aq.	NaHCO3	solution	with	stirring.	The	organic	layer	was	separated	and	washed	with	H2O	(100	mL)	and	brine	(100	mL),	dried	over	MgSO4,	and	concentrated	under	reduced	pressure.	The	crude	nucleoside	was	obtained	as	a	white	foam	 (41	 g)	 and	 was	 used	 directly	 without	 further	 purification;	 silica	 gel	 TLC	 (1:1	hexanes−EtOAc):	Rf	=	0.37.	To	 a	 cold	 (0−5	 °C)	 solution	 containing	 41	 g	 of	 crude	 1-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)thymine	in	THF	(250	mL)	was	added	dropwise	TBAF	(1	M	solution	in	THF,	70.0	mL,	70.0	mmol),	and	the	mixture	was	stirred	for	1	h	at	0−5	°C.	The	solvent	was	evaporated	under	reduced	pressure,	and	the	residue	was	dissolved	in	300	mL	of	EtOAc.	The	organic	layer	was	separated	and	washed	twice	with	H2O	(100	mL)	and	brine	(100	mL),	dried	over	MgSO4,	and	concentrated	under	reduced	pressure	to	give	20	g	of	the	crude	 nucleoside	 as	 a	 yellow	 syrup.	 The	 syrup	 was	 dissolved	 in	 50	 mL	 of	 CH2Cl2	 and	crystallized	 by	 the	 addition	 of	 50	 mL	 of	 hexanes.	 1-(2′-O-Benzoyl-α-L-threofuranosyl)-thymine	 (2.9a)	 was	 obtained	 as	 a	 white	 solid:	 yield	 14.44	 g	 (64%);	 silica	 gel	 TLC	 (1:2	hexanes−EtOAc):	Rf	=	0.35;	1H	NMR	(400	MHz,	CDCl3)	δ	1.90	(s,	3H),	4.05	(brs,	1H),	4.20	(dd,	1H,	J	=	4.4,	10.0	Hz),	4.29	(d,	1H,	J	=	10.0	Hz),	4.51	(brs,	1H),	5.43	(s,	1H),	5.87	(d,	1H,	J	=	2.0	Hz),	7.36	(s,	1H),	7.47	(t,	2H,	J	=	7.6	Hz),	7.61	(t,	1H,	J	=	7.2	Hz),	8.02	(d,	2H,	J	=	8.2	Hz)	and	
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8.90	(brs,	1H);	13C	NMR	(125	MHz,	CD3OD):	δ	12.5,	74.7,	76.5,	83.9,	91.4,	111.2,	129.7,	130.4,	130.8,	134.8,	138.7,	152.3,	166.4,	166.6;	HRMS	(ESI-TOF):	[M	+	Na]+	calcd	for	C16H16N2O6Na,	355.0906;	found,	355.0910.		
N4-Benzoyl-1-(2′-O-benzoyl-α-L-threofuranosyl)cytosine	(2.9b).	To	 a	 solution	 containing	 33.5	 g	 (66.3	 mmol)	 of	 1-O-acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threofuranose	(2.8)	and	15.0	g	(70.0	mmol)	of	N4-benzoylcytosine	in	150	mL	of	anhydrous	acetonitrile	was	added	40.0	mL	(154	mmol)	of	BSA,	and	the	mixture	was	stirred	 for	30	min	at	60	 °C.	TMSOTf	 (38.0	mL,	199	mmol)	was	added	dropwise,	and	stirring	was	continued	at	60	°C	for	another	2	h,	after	which	time	TLC	(1:1	hexanes−EtOAc)	showed	the	reaction	to	be	complete.	The	mixture	was	cooled	to	room	temperature,	diluted	with	200	mL	of	EtOAc,	and	poured	into	200	mL	of	sat.	aq.	NaHCO3	solution	with	stirring.	The	white	suspension	was	filtered	over	Celite		and	the	organic	layer	was	separated	and	washed	with	H2O	(150	mL)	and	brine	(150	mL),	dried	over	MgSO4,	and	concentrated	under	reduced	pressure.	The	crude	nucleoside	was	obtained	as	a	white	foam	(36.0	g)	and	was	used	directly	without	further	purification;	silica	gel	TLC	(EtOAc):	Rf	=	0.75.	To	a	cold	(0−5	°C)	solution	containing	36.0	g	of	crude	N4-benzoyl-1-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)-cytosine	in	THF	(200	mL)	was	added	dropwise	TBAF	(1	M	solution	in	THF,	70.0	mL,	70.0	mmol),	and	the	mixture	was	stirred	at	0−5	°C	for	1	h.	The	solvent	was	evaporated	under	diminished	pressure,	and	the	residue	was	dissolved	in	500	mL	of	EtOAc.	The	organic	layer	was	washed	with	1	N	aq.	HCl	(150	mL)	and	H2O	(150	mL),	and	then	was	stirred	with	brine	(150	mL)	at	r.t.	to	precipitate	the	product.	N4-Benzoyl-1-(2′-O-benzoyl-α-L-threofuranosyl)cytosine	 (2.9b)	 was	 obtained	 as	 a	 white	 solid:	 yield	
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19.4	g	(70%);	silica	gel	TLC	(1:2	hexanes−EtOAc):	Rf	=	0.40;	1H	NMR	(400	MHz,	DMSO-d6)	δ	4.3	(m,	3H),	5.39	(s,	1H),	5.85	(d,	1H,	J	=	2.8	Hz),	5.99	(s,	1H),	7.41	(d,	1H,	J	=	7.2	Hz),	7.50−7.64	(m,	5H),	7.72	(t,	1H,	J	=	7.2	Hz),	8.03	(t,	4H,	J	=	7.6	Hz),	8.22	(d,	1H,	J	=	7.6	Hz),	and	11.27	(s,	1H);	13C	NMR	(125	MHz,	DMSO-d6):	δ	72.4,	76.6,	81.5,	90.9,	95.7,	128.5,	128.9,	129.5,	132.8,	133.2,	 133.9,	 145.7,	 154.5,	 163.4,	 164.5,	 167.4;	 HRMS	 (ESI-TOF):	 [M	 +	 Na]+	 calcd	 for	C22H19N3O6Na,	444.1172;	found,	444.1180.		
N6-Benzoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)adenine	(2.9c).18	A	mixture	of	40.5	g	(80.0	mmol)	of	1-O-acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threofuranose	(2.8)	and	19.1	g	(80.0	mmol)	of	N6-benzoyladenine	was	co-evaporated	with	50	mL	of	anhydrous	toluene	and	then	suspended	in	160	mL	of	anhydrous	toluene.	To	the	suspension	was	added	42.0	mL	(163.8	mmol)	of	BSA,	and	the	mixture	was	stirred	for	30	min	at	95	°C.	Once	all	the	suspension	was	dissolved,	TMSOTf	(22.2	mL,	118.8	mmol)	was	added	dropwise,	and	stirring	was	continued	at	95	°C	 for	another	2.5	h,	after	which	TLC	showed	complete	 consumption	 of	 the	 starting	 material	 and	 more	 polar	 major	 products	corresponding	 to	 the	N9	 glycosides.	 The	mixture	was	 cooled	 to	 room	 temperature,	 then	poured	into	a	stirring	mixture	of	150	g	of	ice	and	150	mL	of	sat.	aq.	NaHCO3	solution	and	stirred	for	30	min.	The	organic	layer	was	separated	and	washed	with	H2O	(50	mL)	and	brine	(50	mL),	dried	over	MgSO4,	and	concentrated	under	reduced	pressure.	The	crude	nucleoside	was	obtained	as	a	yellow	foam:	yield	54.3	g.	To	a	cold	(0−5	°C)	solution	(ice-bath)	containing	54.3	g	of	N6-benzoyl-9-(2′-O-benzoyl-3′-
O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	in	THF	(160	mL)	was	added	dropwise	TBAF	(1	M	solution	in	THF,	80.0	mL,	80.0	mmol),	and	the	mixture	was	stirred	at	0−5	°C	for	
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30	 min.	 The	 solvent	 was	 evaporated	 under	 diminished	 pressure,	 and	 the	 residue	 was	dissolved	in	200	mL	of	EtOAc.	The	organic	layer	was	washed	with	H2O	(50	mL)	and	brine	(50	mL).	The	combined	aqueous	layer	was	back-extracted	with	EtOAc	(2	×	50	mL).	The	combined	organic	layer	was	dried	over	MgSO4	and	concentrated	under	reduced	pressure.	The	resulting	crude	material	was	dissolved	in	150	mL	of	1%	methanol	in	CH2Cl2	and	crystallized	by	slow	addition	 of	 120	 mL	 of	 hexanes.	 N6-Benzoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)adenine	(2.9c)	was	obtained	as	a	white	solid:	yield	15.5	g	(43.5%);	silica	gel	TLC	(EtOAc):	Rf	=	0.35;	1H	NMR	(400	MHz,	CDCl3)	δ	4.30	(dd,	1H,	J	=	4.0,	10.0	Hz),	4.39	(d,	1H,	J	=	10.0	Hz),	4.67	(d,	1H,	J	=	3.2	Hz),	5.63	(s,	1H),	6.07	(d,	1H,	J	=	1.6	Hz),	7.56	(m,	6H),	8.04	(t,	4H,	J	=	8.1	Hz),	8.27	(s,	1H),	and	8.81	(s,	1H).		
N2-Acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-α-L-threo-furanosyl)guanine	2.9d).	To	a	solution	containing	8.45	g	(26.1	mmol)	of	N2-acetyl-O6-diphenylcarbamoyl	guanine	in	200	mL	of	a	mixture	of	anhydrous	dichloroethane	and	toluene	(1:2	v/v)	was	added	15.8	mL	(64.6	mmol)	of	N,O-bis(trimethylsilyl)acetamide,	and	the	mixture	was	stirred	for	30	min	at	70	°C.	The	solvent	was	removed	under	reduced	pressure,	and	the	residue	was	dissolved	in	 55	 mL	 of	 anhydrous	 toluene.	 1-O-Acetyl-2-O-benzoyl-3-O-tert-butyldiphenyl-silyl-L-threofuranose	(2.8)	(11	g,	21.8	mmol)	in	65	mL	of	anhydrous	toluene	was	added	dropwise	using	a	canula,	and	the	mixture	was	heated	to	70	°C.	TMSOTf	(8.5	mL,	45.9	mmol)	was	then	added	dropwise,	and	the	mixture	was	stirred	at	70	°C	for	another	1.5	h,	after	which	TLC	(1:1	hexanes−EtOAc)	showed	complete	consumption	of	(2.8).	The	mixture	was	cooled	to	room	temperature,	 diluted	with	300	mL	of	 EtOAc,	 and	poured	 into	 150	mL	of	 sat.	 aq.	NaHCO3	solution	with	stirring,	resulting	in	a	purple	suspension.	The	suspension	was	filtered,	and	the	
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organic	layer	was	separated	and	washed	with	H2O	(150	mL)	and	brine	(150	mL),	dried	over	MgSO4,	and	concentrated	under	reduced	pressure.	The	crude	nucleoside	was	obtained	as	a	purple	foam	(16.12	g)	and	was	used	directly	without	further	purification;	silica	gel	TLC	(1:2	hexanes−EtOAc):	Rf	=	0.7.	To	a	cold	(0−5	°C)	solution	containing	16.12	g	of	crude	N2-acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)	 guanine	 in	 THF	 (50	 mL)	was	added	dropwise	TBAF	(1	M	solution	in	THF,	19.0	mL,	19.0	mmol),	and	the	mixture	was	stirred	at	0−5	°C.	After	15	min,	TLC	was	checked	and	another	9	mL	of	TBAF	was	added,	and	the	mixture	was	stirred	for	45	min.	The	solvent	was	evaporated	under	diminished	pressure,	and	the	residue	was	dissolved	in	250	mL	of	EtOAc.	The	organic	layer	washed	with	1	N	aq.	HCl	(50	mL),	H2O	(50	mL),	and	brine	(50	mL),	was	dried	over	MgSO4,	and	concentrated	under	reduced	 pressure.	 The	 resulting	 crude	 product	 was	 dissolved	 in	 CH2Cl2	 (30	 mL)	 and	crystallized	by	addition	of	an	equal	amount	of	hexanes.	N2-Acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)-guanine	(2.9d)	was	obtained	as	a	white	solid:	yield	8.9	g	(69%);	silica	gel	TLC	(1:2	hexanes−EtOAc):	Rf	=	0.25;	1H	NMR	(400	MHz,	DMSO-d6)	δ	2.20	(s,	3H),	4.32	(dq,	2H,	J	=	3.6,	7.6	Hz),	4.60	(m,	1H),	5.78	(t,	1H,	J	=	2.0	Hz),	5.96	(d,	1H,	J	=	4.0	Hz),	6.31	(d,	1H,	J	=	1.6	Hz),	7.33	(t,	2H,	J	=	6.0	Hz),	7.43−7.60	(m,	10H),	7.72	(t,	1H,	J	=	6.0	Hz),	8.03	(dd,	1H,	J	=	0.8,	6.4	Hz),	8.60	(s,	1H),	and	10.81	(s,	1H);	13C	NMR	(125	MHz,	DMSO-
d6)	δ	24.6,	73.2,	74.8,	82.3,	87.9,	120.1,	128.7,	128.9,	129.5,	129.6,	134.0,	141.6,	144.3,	150.1,	152.3,	 154.2,	 155.3,	 165.0,	 169.2;	 HRMS	 (ESI-TOF):	 [M	 +	 Na]+	 calcd	 for	 C31H26N6O7Na,	617.1761;	found,	617.1750.	
1-(3′-O-Dimethoxytrityl-α-L-threofuranosyl)thymine	(2.10a).15	
35		
A	mixture	containing	3.2	g	 (9.6	mmol)	of	1-(2′-O-benzoyl-α-L-threofuranosyl)thymine	(2.9a),	4.88	g	(14.4	mmol,	1.5	equiv)	of	DMT-Cl,	and	100	mg	of	DMAP	(0.82	mmol)	was	co-evaporated	twice	with	20.0	mL	of	anhydrous	pyridine.	The	mixture	was	dissolved	in	40	mL	of	anhydrous	pyridine	and	stirred	under	argon	at	80	°C	for	16	h.	The	solvent	was	evaporated	under	diminished	pressure,	and	the	residue	was	partitioned	between	EtOAc	(50	mL)	and	H2O	 (50	 mL).	 The	 organic	 layer	 was	 washed	 with	 brine	 (50	 mL),dried	 (MgSO4)	 and	evaporated.	The	residue	was	dissolved	in	a	mixture	of	38	mL	of	THF	and	30.5	mL	of	MeOH,	and	then	cooled	to	0	°C.	To	the	cold	solution	was	added	15.0	mL	of	ice-cold	1	N	aq.	NaOH	while	stirring.	After	30	min,	the	reaction	was	quenched	by	addition	of	100	mL	of	water.	The	volatile	solvent	was	removed	under	diminished	pressure,	and	the	residual	aqueous	solution	was	extracted	with	EtOAc	(3	×	50	mL).	The	combined	organic	layer	was	dried	(MgSO4)	and	evaporated.	The	residue	was	purified	on	a	silica	gel	column	(50	g	silica	bed),	eluting	with	50−100%	EtOAc	in	hexanes	containing	2%	Et3N	in	steps	of	5%	increase	in	EtOAc	for	every	200	 mL.	 1-(3′-O-Dimethoxytrityl-α-L-threofuranosyl)thymine	 (2.10a)	 was	 obtained	 as	 a	white	foam:	yield	3.6	g	(71%);	1H	NMR	(400	MHz,	CDCl3):	δ	1.82	(s,	3H),	3.30	(d,	1H,	J	=	9.6	Hz),	3.67	(s,	3H),	3.71	(s,	3H),	3.91	(d,	1H,	J	=	13.6	Hz),	4.19	(s,	1H),	4.23	(s,	1H),	5.72	(s,	1H),	6.79	(m,	4H),	7.12−7.38	(m,	9H),	7.44	(s,	1H)	and	10.92	(s,	1H).	
	
N4-Benzoyl-1-(3′-O-dimethoxytrityl-α-L-threofuranosyl)-cytosine	(2.10b).15	A	 mixture	 of	 3.18	 g	 (7.7	 mmol)	 of	 N4-benzoyl-1-(2′-O-benzoyl-α-L-threofuranosyl)cytosine	 (2.9b),	 3.84	 g	 (11.3	mmol,	 1.5	 equiv)	 of	DMT-Cl,	 and	 120	mg	 of	DMAP	(0.99	mmol,	0.1	equiv)	was	coevaporated	twice	with	15.0	mL	of	anhydrous	pyridine.	The	residue	was	suspended	in	50	mL	of	anhydrous	pyridine	and	stirred	under	argon	for	16	
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h	 at	 80	 °C.	The	 solvent	was	 evaporated	under	diminished	pressure,	 and	 the	 residue	was	partitioned	between	EtOAc	(50	mL)	and	H2O	(50	mL).	The	organic	layer	was	washed	with	brine	(50	mL),	dried	(MgSO4),	and	evaporated.	The	residue	was	dissolved	in	a	mixture	of	38	mL	of	THF	and	30.5	mL	of	MeOH,	and	then	cooled	to	0	°C.	To	the	cold	solution	was	added	7.7	mL	of	ice-cold	1	N	aq.	NaOH	while	stirring.	After	10	min,	another	7.7	mL	of	ice-cold	1	N	aq.	NaOH	was	 added.	 Ten	minutes	 after	 the	 second	 addition,	 the	 reaction	was	 quenched	 by	addition	 of	 40	 mL	 of	 10%	 NH4Cl	 in	 water.	 The	 volatile	 solvent	 was	 removed	 under	diminished	pressure,	and	the	residue	was	diluted	by	addition	of	50	mL	of	EtOAc.	The	organic	layer	 was	 separated,	 washed	 with	 H2O	 (50	mL)	 and	 brine	 (50	mL),	 dried	 (MgSO4),	 and	evaporated.	The	residue	was	purified	on	a	silica	gel	column	(50	g	silica	bed),	eluting	with	70−100%	EtOAc	in	hexane	containing	1%	Et3N	in	steps	of	5%	increase	in	EtOAc	for	every	200	 mL.	 N4-Benzoyl-1-(3′-O-dimethoxytrityl-α-L-threofuranosyl)cytosine	 (2.10b)	 was	obtained	as	a	white	foam:	yield	3.12	g	(65%);	1H	NMR	(400	MHz,	CDCl3):	δ	3.32	(d,	1H,	J	=	10.0	Hz),	3.71	(d,	1H,	J	=	4.0	Hz),	3.74	(s,	6H),	4.25	(s,	1H),	4.33	(s,	1H),	5.70	(s,	1H),	6.79	(m,	4H),	6.75−7.35	(m,	9H),	7.47−7.67	(m,	4H),	7.94	(d,	2H,	J	=	8.0	Hz),	8.05	(d,	1H,	J	=	8.0	Hz),	and	9.10	(brs,	1H).	
	
N6-Benzoyl-9-(3′-O-dimethoxytrityl-α-L-threofuranosyl)adenine	(2.10c).15	A	 mixture	 of	 3.39	 g	 (7.6	 mmol)	 of	 N6-benzoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)adenine	(2.9c),	3.86	g	(11.4	mmol,	1.5	equiv)	of	DMT-Cl,	and	93	mg	(0.76	mmol,	0.1	equiv)	of	DMAP	was	co-evaporated	twice	with	7.0	mL	of	anhydrous	pyridine.	The	residue	was	dissolved	in	35	mL	of	anhydrous	pyridine,	and	the	mixture	was	stirred	at	75	°C	under	 argon	 for	 16	 h.	 The	 solvent	 was	 evaporated	 under	 diminished	 pressure,	 and	 the	
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residue	was	partitioned	between	EtOAc	(50	mL)	and	H2O	(50	mL).	The	organic	layer	was	washed	with	brine	(50	mL),	dried	(MgSO4),	and	evaporated.	The	residue	was	dissolved	in	a	mixture	of	38	mL	of	THF	and	30.5	mL	of	MeOH,	and	then	cooled	to	0	°C.	To	the	cold	stirred	solution	was	added	7.6	mL	of	ice-cold	1	N	aq.	NaOH	solution.	After	10	min,	another	7.6	mL	of	ice-cold	 1	 N	 aq.	 NaOH	 solution	 was	 added.	 Ten	 minutes	 after	 the	 second	 addition,	 the	reaction	was	quenched	with	40	mL	of	 10%	aq.	NH4Cl.	 The	 volatile	 solvent	was	 removed	under	diminished	pressure,	and	the	aqueous	residue	was	diluted	with	50	mL	of	EtOAc.	The	organic	layer	was	separated,	washed	with	H2O	(50	mL)	and	brine	(50	mL),	dried	(MgSO4),	and	evaporated.	The	residue	was	purified	on	a	silica	gel	column	(70	g	silica	bed),	eluting	with	30−80%	EtOAc	in	hexanes	containing	1%	Et3N.	Stepwise	elution	was	performed	with	10%	increases	 in	 EtOAc	 for	 each	 200	 mL	 volume.	 N6-Benzoyl-9-(3′-O-dimethoxytrityl-α-L-threofuranosyl)adenine	(1.10c)	was	obtained	as	a	white	foam:	yield	3.6	g	(63%);	1H	NMR	(400	MHz,	DMSO-d6)	3.45	(dd,	1H,	J	=	5.2,	9.6	Hz),	3.59	(dd,	1H,	J	=	3.2,	9.6	Hz),	3.73	(s,	6H),	4.17	(m,	1H),	4.50	(m,	1H),	5.91	(d,	1H,	 J	=	2.8	Hz),	5.93	(d,	1H,	 J	=	4.8	Hz),	6.86	(m,	4H),	7.13−7.33	(m,	9H),	7.56	(t,	2H,	J	=	7.6	Hz),	7.65	(t,	1H,	J	=	7.2	Hz),	8.06	(d,	2H,	J	=	7.2	Hz),	8.56	(s,	1H),	8.75	(s,	1H),	11.22	(brs,	1H).		
N2-Acetyl-O6-diphenylcarbamoyl-9-(3′-O-dimethoxytrityl-α-L-threofuranosyl)	
guanine	(2.10d).15	5.2	 g	 (8.74	 mmol)	 of	 N2-acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)guanine	(2.9d)	was	coevaporated	with	20	mL	of	anhydrous	pyridine	under	reduced	pressure,	and	the	solid	residue	was	dried	under	vacuum	for	18	h.	To	the	residue	was	added	5.92	g	(17.48	mmol,	2	equiv)	of	DMT-Cl,	anhydrous	dichloromethane	(60	mL),	2.3	mL	
38		





2008,	130,	15105.	4. Orgel,	L.	E.	Science,		2000,	290,	1306.	5. Joyce,	G.	F.	Nature,		2002,	418,	214.	6. Chaput,	J.	C.;	Yu,	H.;	Zhang,	S.	Chem.	Biol.	2012,	19,	1360.	7. Chaput,	J.	C.;	Szostak,	J.	W.	J.	Am.	Chem.	Soc.	2003,	125,	9274.	8. Chaput,	J.	C.;	Ichida,	J.	K.;	Szostak,	J.	W.	J.	Am.	Chem.	Soc.	2003,	125,	856.	9. Kempeneers,	V.;	Vastmans,	K.;	Rozenski,	J.;	Herdewijn,	P.	Nucleic	Acids	Res.	2003,	31,	6221.	10. Horhota,	A.;	Zou,	K.;	Ichida,	J.	K.;	Yu,	B.;	McLaughlin,	L.	W.;	Szostak,	J.	W.;	Chaput,	J.	C.	
J.	Am.	Chem.	Soc.	2005,	127,	7427.	11. Yu,	H.;	Zhang,	S.;	Dunn,	M.;	Chaput,	J.	C.	J.	Am.	Chem.	Soc.	2013,	135,	3583.	12. Dunn,	M.	R.;	Larsen,	A.	C.;	Fahmi,	N.;	Zahurancik,	W.	J.;	Meyers,	M.;	Suo,	Z.;	Chaput,	J.	C.	J.	Am.	Chem.	Soc.	2015,	137,	4014.	13. Yu,	H.;	Zhang,	S.;	Chaput,	J.	C.	Nat.	Chem.	2012,	4,	183.	14. Zou,	K.;	Horhota,	A.;	Yu,	B.;	Szostak,	J.	W.;	McLaughlin,	L.	W.	Org.	Lett.	2005,	7,	1485.	15. Schoning,	K.-U.;	Scholz,	P.;	Wu,	X.;	Guntha,	S.;	Delgado,	G.;	Krishnamurthy,	R.;	Eschenmoser,	A.	Helv.	Chim.	Acta.	2002,	85,	4111.	16. Zhang,	S.;	Yu,	H.;	Chaput,	J.	C.	Curr.	Protoc.	Nucleic	Acid	Chem.	2013,	52,	4.54.1.	
40		


















Publication	Note	This	paper	was	originally	published	in	the	Journal	Of	Organic	Chemistry.	Saikat	Bala†,	Jen-Yu	Liao†,	Hui	Mei,	and	John	C.	Chaput*	Synthes	 is	 of	 α-L-Threofuranosyl	 Nucleoside-3′-Monophosphates,	 3′-Phosphoro(2-Methyl)imidazolides,	 and	 3′-Triphosphates.	 	 J.	 Org.	 Chem,	 2017,	 82,	 5910−5916.	 (†	 equal	contribution)	Copyright	©	2017	American	Chemical	Society		
3.1	Contribution	Statement		Bala,	S.	and	Chaput,	J.	C.	designed	the	synthetic	strategy.	All	authors	contributed	to	the	synthesis,	 optimization,	 and	 characterization	 of	 the	 synthetic	 compounds.	 All	 authors	contributed	to	the	manuscript	writing	with	the	comments	from	Mei,	H.		
3.2	Abstract	of	the	Chapter	α-L-Threofuranosyl	 nucleic	 acid	 (TNA)	 is	 an	 artificial	 genetic	 polymer	 composed	 of	vicinal	2′,3′-phosphodiester	bonds	 linking	adjacent	 to	 threofuranosyl	nucleosides.	TNA	 is	one	of	a	small	number	of	genetic	polymers	that	capable	of	cross-pairing	with	DNA	and	RNA	and	are	resistant	to	nuclease	digestion.	Although	an	efficient	approach	has	been	reported	for	
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synthesizing	 TNA	 nucleosides,	 very	 few	 advances	 have	 been	 made	 in	 the	 synthesis	 of	phosphorylated	 TNA	 compounds.	 Here,	 we	 describe	 an	 highly	 efficient	 method	 for	synthesizing	α-L-threofuranosyl	nucleoside	3′-monophosphates	(tNMPs),	3′-phosphoro(2-methyl)imidazolides	(2-MeImptNs),	and	3′-triphosphates	(tNTPs)	bearing	the	four	genetic	bases	 of	 adenine	 (A),	 cytosine	 (C),	 thymine	 (T),	 and	 guanine	 (G).	 We	 suggest	 that	 this	strategy,	which	provides	access	to	grams	of	tNMPs,	hundreds	of	milligrams	of	2-MeImptNs,	and	 tens	 of	 milligrams	 of	 tNTPs,	 will	 help	 advance	 the	 use	 of	 TNA	 monomers	 in	 the	downstream	exobiology	and	biotechnology	applications.		
	
3.3	Introduction		Nucleoside	 triphosphates	 are	 indispensable	 reagents	 for	 a	 broad	 range	 of	 synthetic	biology,	 molecular	 biology	 and	 biotechnology	 applications.1−3	 Particularly,	 modified	nucleoside	 triphosphates	 that	 carry	new	chemical	moieties	 at	 the	 sugar,	 nucleobase,	 and	phosphate	positions	are	critical	to	many	therapeutic	and	diagnostic	applications,4−7	as	well	as	 fundamental	 studies	 intended	 for	 evaluating	 the	 specificity	 of	 natural	 enzymes	 or	identifying	emergent	properties	of	life	either	here	on	Earth	or	elsewhere	in	the	universe.8	Unfortunately,	despite	extensive	efforts	to	develop	chemical	and/or	enzymatic	strategies	for	producing	nucleoside	triphosphates,	no	universal	strategy	has	been	developed	that	can	be	applied	to	all	nucleosides.9	This	is	especially	true	for	chemically	modified	analogues	where	a	 large	 number	 of	 synthetic	 methods	 have	 been	 developed	 to	 accommodate	 the	idiosyncrasies	 of	 different	 nucleoside	 chemistries.10−14	 As	 expected,	 each	 strategy	 comes	with	its	own	strengths	and	weaknesses	that	must	be	evaluated	on	a	case-by-case	basis.15	In	general,	 enzymatic	 strategies	 suffer	 from	poor	substrate	 specificity,	 scale,	 yield,	 and	cost,	
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whereas	chemical	approaches	struggle	with	functional	group	compatibility,	regiochemistry,	yield,	and	purification.	15	Synthesizing	nucleoside	triphosphates	of	α-L-threofuranosyl	nucleic	acid	(TNA)	requires	phosphorylating	the	3′-hydroxyl	position	on	the	furanose	ring.16	However,	the	3′-hydroxyl	position	of	α-L-threofuranosyl	nucleosides	is	substantially	less	reactive	than	the	5′-	hydroxyl	position	of	DNA	and	RNA	nucleosides	because	secondary	alcohols	are	less	nucleophilic	than	primary	 alcohols	 and	 the	 3′-position	 is	more	 sterically	 encumbered	 than	 the	 normal	 5′-hydroxyl	position	of	ribose	sugar	(Figure	3-1).								
	
Figure	3-1.	Molecular	structure	of	TNA	and	RNA.		Given	the	importance	of	TNA	building	blocks	in	many	exobiology	and	synthetic	biology	projects,	a	concerted	effort	has	been	made	to	develop	synthetic	approaches	for	constructing	phosphorylated	TNA	compounds	(Scheme	3-1)	on	the	scales	required	to	meet	the	needs	of	current	downstream	applications.17−20	Early	efforts	by	our	laboratory	and	others	applying	the	 Yoshikawa	method	with	 POCl3	 proved	 unsuccessful	 due	 to	 unwanted	 side	 reactions.	
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Szostak	and	co-workers	overcame	this	problem	using	the	classic	Ludwig−Eckstein	method,	which	was	achieved	all	 four	TNA	 triphosphates	 synthesis	 from	 their	 corresponding	2′-O-DMT	protected	nucleosides.21	Although	 a	 detailed	 protocol	 was	 subsequently	 established,22	 this	 method	 proved	cumbersome	due	to	the	poor	regioselectivity	observed	when	TNA	nucleosides	are	tritylated	on	3’-OH	with	DMT.21	As	an	alternative	strategy,	we	developed	a	one-pot	four-step	synthesis	of	TNA	triphosphates	from	their	2′-O-benzoyl	derivatives	that	is	considerably	less	sensitive	





	 To	overcome	the	shortcomings	of	previous	methods,	we	developed	a	robust	strategy	for	generating	TNA	nucleoside	monophosphates,	monophosphate	derivatives,	and	nucleoside	triphosphates	 that	 is	 straightforward	 to	 perform	 and	 could	 be	 transferrable	 to	 other	modified	 nucleosides.	 Our	 approach	 consists	 of	 four	 synthetic	 steps	 to	 generate	 TNA	 28		monophosphates	 from	 a	 TNA	 nucleoside	 intermediate	 that	 can	 be	 produced	 in	 large	quantities	 from	 L-ascorbic	 acid.24	 TNA	 3′-monophosphates	 are	 then	 converted	 to	 3′-phosphoro(2-methyl)imidazolides,	 which	 are	 reacted	 with	 pyrophosphate	 to	 produce	nucleoside	3′-triphosphates.	HPLC	analysis	of	the	crude	reaction	mixture	indicates	that	the	
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phosphorylation	steps	proceed	cleanly	with	high	yield	of	the	desired	compounds.	We	suggest	that	the	current	strategy	will	be	useful	for	constructing	TNA	nucleotides	for	a	wide	range	of	molecular	biology	and	biotechnology	applications,	as	TNA	nucleoside	3′-monophosphates,	3′-monophosphate	derivatives,	 and	3′-triphosphates	 are	obtained	 as	 isolated	 compounds	that	can	be	stored	for	long	periods	of	time	without	degradation.		































































































we	 30	 found	 that	 the	 higher	 reactivity	 of	 the	 chlorophosphoramidite	 reagent	 by	 P(III)	chemistry,	coupled	with	the	ability	to	purify	the	nucleoside	monophosphate	precursor	3.3a-
d	by	silica	gel	chromatography,	provided	an	efficient	method	for	obtaining	large	quantities	(grams)	of	highly	pure	TNA	3′-monophosphates.	Next,	TNA	monophosphates	3.4a−d	were	converted	to	their	3′-phosphoro(2-	methyl)-imidazolide	 derivatives	 3.5a−d	 using	 classic	 methodology	 previously	 developed	 by	Mukaiyama	 and	 co-workers.26	 Accordingly,	 a	 Mitsunobu-like	 reaction	 is	 performed	 by	incubating	3.4a−d	with	excess	2-methylimidazole	and	triphenylphosphine	in	the	presence	of	2,2′-dipyridyldisulfide	under	basic	reaction	condition.	In	some	cases,	complete	conversion	of	 the	starting	material	required	the	addition	of	excess	amount	of	2-methylimidazole	and	triphenylphosphine.	 The	 desired	 TNA	 nucleoside	 3′-phosphoro-(2-methyl)imidazolides	

















	TNA	nucleoside	3′-triphosphates	3.6a−d	were	synthesized	from	the	activated	nucleoside	monophosphates	3.5a−d	by	displacing	the	activated	2-methylimidazole	leaving	group	with	pyrophosphate.	 In	 these	 reactions,	 TNA	 nucleosides	 3.5a−d	 were	 incubated	tributylammonium	pyrophosphate	and	tributylamine	in	a	DMF	solution	for	8−12	h	at	room	temperature.	The	reaction	was	monitored	by	analytical	HPLC,	and	additional	pyrophosphate	and	tributylamine	were	added	as	needs	to	drive	the	reaction	to	completion	(Figure	3-2).	In	
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(Table		was	used	with	permission	from	.		J.	Org.	Chem,	2017,	82,	5910−5916.)		To	confirm	that	tNTPs	synthesized	using	our	new	strategy	can	function	as	substrates	for	an	engineered	TNA	polymerase,	we	performed	a	standard	primer-extension	assay	in	which	a	library	of	DNA	templates	were	copied	into	TNA	product.	To	date,	the	polymerase	that	most	efficiently	 uses	 tNTP	 substrates	 is	 Kod-RI,	 a	 polymerase	 that	 was	 developed	 through	 a	combination	 of	 directed	 evolution	 and	 scaffold	 sampling.20,27	 Kod-RI	 functions	 with	 a	catalytic	rate	of	∼1	nucleotide	per	minute	and	is	able	to	copy	most	DNA	templates	into	TNA.27	As	a	demonstration,	an	IR-labeled	DNA	primer	was	annealed	to	a	degenerate	DNA	library	and	 incubated	with	Kod-RI	 in	 the	presence	of	 chemically	 synthesized	of	 tNTP	substrates.	Analysis	of	the	primer-extension	reaction	by	denaturing	polyacrylamide	gel	electrophoresis	(Figure	3-3)	reveals	that	the	primer	is	extended	to	full-length	product	after	a	3	h	incubation	at	55	°C.	This	result,	which	is	consistent	with	the	known	activity	of	Kod-RI,27	demonstrates	that	 the	 new	 synthetic	 approach	 produces	 TNA	 triphosphates	 that	 are	 recognized	 by	 an	engineered	TNA	polymerase.								
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Figure	3-3.	Primer-extension	analysis	
(Figure	was	used	with	permission	from	.		J.	Org.	Chem,	2017,	82,	5910−5916.)	A	5′-IR-labeled	DNA	primer	annealed	to	a	DNA	template	was	extended	with	70	sequential	TNA	 residues.	 Polymerization	 reaction	 was	 performed	 at	 55	 °C	 for	 3	 h	 using	 Kod-RI	 TNA	polymerase	 and	 chemically	 synthesized	 tNTPs.	 The	 reaction	 was	 analyzed	 by	 denaturing	polyacrylamide	gel	electrophoresis.			
	












cytosine	(3.3b).	To	 a	 stirring	 solution	 containing	 1	 g	 (2.3	 mmol)	 of	 N4-benzoyl-1-(2′-O-benzoyl-α-L-threofuranosyl)cytosine	 (3.1b)24	 and	 290	mg	 (2.3	mmol)	 of	 DMAP	 in	 12	mL	 anhydrous	CH2Cl2	was	added	1	mL	(5.9	mmol)	of	N,N′-diisopropylethylamine	followed	by	the	addition	of	 1.05	 mL	 (4.7	 mmol)	 of	 2-cyanoethoxy-N,N’-diisopropylchlorophosphoramidite.	 After	being	stirred	for	40	min	at	room	temperature,	the	reaction	mixture	was	diluted	with	40	mL	of	CH2Cl2	and	extracted	twice	with	50	mL	of	saturated	aqueous	NaHCO3,	washed	with	brine,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	N4-benzoyl-1-[2′-O-benzoyl-3′-O-(N,N’-diisopropylamino-2-cyanoethoxy-phosphinyl)-α-L-threofuranosyl]cyto-	sine	(3.2b)23	was	used	without	further	purification.	To	 a	 stirring	 solution	 containing	 crude	 N4-benzoyl-1-[2′-O-benzoyl-3′-O-(N,N’-diisopropylamino-2-cyanoethoxyphosphinyl)-α-L-threofuranosyl]	 cytosine	 (2.2b)23	 in	 10	mL	 of	 anhydrous	 acetonitrile	 was	 added	 0.65	 mL	 (7.1	 mmol)	 of	 3-hydroxypropionitrile	followed	by	the	addition	of	21.07	mL	of	tetrazole	(0.45	M	solution	in	anhydrous	acetonitrile,	9.48	mmol).	The	reaction	mixture	was	stirred	for	1.5	h	at	room	temperature	with	monitoring	by	TLC	(1:1	hexanes−EtOAc).	After	complete	consumption	of	 the	starting	material,	 to	 the	reaction	was	added	10	mL	of	30%	H2O2	and	left	to	stir	for	20	min	at	room	temperature.	The	crude	product	 solution	was	 evaporated	 to	 dryness	 and	 re-dissolved	with	50	mL	of	 ethyl	
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acetate.	 The	 organic	 layer	 was	 washed	 with	 brine	 and	 water,	 dried	 over	 MgSO4,	 and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	with	silica	gel	column	chromatography	 affording	 N4-(2′-O-benzoyl-3′-O-[bis(2-cyanoethyoxy)phosphoryl]-α-L-threofuranosyl)cytosine	 (3.3b)	 as	 a	 white	 foam:	 yield	 0.68	 g	 (47.2%);	 silica	 gel	 TLC	(DCM/acetone,	10:1)	Rf	=	0.35;	1H	NMR	(400	MHz,	DMSO-d6)	δ	11.30	(s,	1H),	8.21	(d,	1H,	J	=	7.2	Hz),	8.00−8.07	(m,	4H),	7.73	(t,	1H,	J	=	7.6	Hz),	7.57−7.65	(m,	3H),	7.52	(t,	2H,	J	=	7.2	Hz),	7.44	(d,	1H,	J	=	6.4	Hz),	6.07	(d,	1H,	J	=	1.2	Hz),	5.73	(d,	1H,	J	=	1.2	Hz),	5.21	(m,	1H),	4.63	(d,	1H,	J	=	10.4	Hz),	4.47	(dd,	1H,	J	=	3.6,	10.4	Hz),	4.23	(m,	4H),	2.94	(m,	4H);	13C	NMR	(100.6	MHz,	DMSO-d6)	δ	167.4,	164.4,	163.7,	154.5,	145.1,	134.1,	133.2,	132.8,	129.7,	128.9,	128.6,	128.5,	118.1,	118.0,	96.3,	90.9,	79.5	(d,	JC,P	=	6.3	Hz),	78.2	(d,	JC,P	=	5.0	Hz),	74.1	(d,	JC,P	=	3.8	Hz),	63.1	(d,	JC,P	=	4.9	Hz),	63.1	(d,	JC,P	=	4.9	Hz),	19.1	(d,	JC,P	=	7.4	Hz),	19.0	(d,	JC,P	=	7.5	Hz);	31P	NMR	(162	MHz,	DMSO-d6)	δ	−2.61;	HRMS	(ESI-TOF)	calcd	for	C28H26N5O9Pna	[M	+	Na]+	630.1366;	found	630.1382.		
N6-(2′-O-Benzoyl-3′-O-[bis(2-cyanoethyoxy)phosphoryl]-α-L-threofuranosyl)adeni-
ne	(3.3c).	To	 a	 stirring	 solution	 containing	 1	 g	 (2.2	 mmol)	 of	 N6-benzoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)	 adenine	 (3.1c)24	 and	 273	mg	 (2.2	mmol)	 of	 DMAP	 in	 12	mL	 anhydrous	CH2Cl2	 was	 added	 0.78	 mL	 (4.4	 mmol)	 of	 N,N′-diisopropylethylamine	 followed	 by	 the	addition	of	0.85	mL	(3.8	mmol)	of	2-cyanoethoxy-N,N’-diisopropylchlorophosphoramidite.	After	being	stirred	for	40	min	at	room	temperature,	the	reaction	mixture	was	diluted	with	40	mL	of	CH2Cl2	and	extracted	twice	with	50	mL	of	saturated	aqueous	NaHCO3,	washed	with	brine,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	N6-benzoyl-9-
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phoryl]-α-L-threofuranosyl)	guanine(3.3d).	To	a	stirring	solution	containing	1	g	(1.7	mmol)	of	N2-acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)	guanine	(3.1d)24	and	210	mg	(1.68	mmol)	of	DMAP	in	12	mL	 anhydrous	 CH2Cl2	 was	 added	 0.58	 mL	 (3.4	 mmol)	 of	 N,N′-diisopropylethylamine	followed	 by	 the	 addition	 of	 0.821	 mL	 (3.7	 mmol)	 of	 2-cyanoethoxy-N,N’-diisopropylchlorophosphoramidite.	After	being	stirred	for	40	min	at	room	temperature,	the	reaction	 mixture	 was	 diluted	 with	 40	 mL	 of	 CH2Cl2	 and	 extracted	 twice	 with	 50	 mL	 of	saturated	aqueous	NaHCO3,	washed	with	brine,	dried	over	MgSO4,	and	evaporated	under	reduced	 pressure.	 The	 crude	 N2-acetyl-O6-diphenylcarbamoyl-9-[2′-O-benzoyl-3′-O-(N,N’-diisopropylamino-2-cyanoethoxyphosphinyl)-α-L-threofuranosyl]guanine	 (3.2d)23	 was	used	without	further	purification.	To	a	stirring	solution	containing	crude	N2-acetyl-O6-diphenylcarbamoyl-9-[2′-O-benzoyl-3′-O-(N,N’-diisopropylamino-2-cyanoethoxy-phosphinyl)-α-L-threofuranosyl]	 guanine	(3.2d)23	 in	 10	 mL	 of	 anhydrous	 acetonitrile	 was	 added	 0.36	 mL	 (5.0	 mmol)	 of	 3-hydroxypropionitrile	 followed	by	the	addition	of	14.9	mL	of	 tetrazole	(0.45	M	solution	 in	anhydrous	 acetonitrile,	 6.7	 mmol).	 The	 reaction	 mixture	 was	 stirred	 for	 1.5	 h	 at	 room	temperature	with	monitoring	by	TLC	(1:1	hexanes−EtOAc).	After	complete	consumption	of	the	starting	material,	to	the	reaction	was	added	10	mL	of	30%	H2O2	and	left	to	stir	for	20	min	at	 room	 temperature.	 The	 crude	 product	 solution	 was	 evaporated	 to	 dryness	 and	redissolved	with	50	mL	of	ethyl	acetate.	The	organic	layer	was	washed	with	brine	and	water,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	with	silica	gel	column	chromatography	affording	N2-acetyl-O6-diphenylcarbamoyl-9-(2′-O_-
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benzoyl-3′-O-[bis(2-cyanoethyoxy)-phosphoryl]-α-L-threofuranosyl)guanine	 (3.3d)	 as	 a	white	foam:	yield	0.59	g	(45%);	silica	gel	TLC	(DCM/acetone,	10:1)	Rf	=	0.35;	1H	NMR	(500	MHz,	DMSO-d6)	δ	10.78	(s,	1H),	8.55	(s,	1H),	8.03	(d,	2H,	J=	7.5	Hz),	7.71	(t,	1H,	J	=	7.5	Hz),	7.44−7.57	(m,	10H),	7.33	(t,	2H,	J	=	6.5	Hz),	6.39	(s,	1H),	6.21	(s,	1H),	5.41	(s,	1H),	4.75	(m,	1H),	4.47	(m,	1H),	4.24	(m,	4H),	2.94	(m,	4H),	2.20	(s,	3H);	13C	NMR	(125.8	MHz,	DMSO-d6)	
δ	_168.9,	164.8,	155.3,	154.2,	152.4,	150.1,	144.0,	141.6,	134.1,	129.7,	129.5,	128.9,	128.4,	127.4,	120.3,	118.2,	118.0,	116.7,	87.3,	79.5	(d,	J	C,P	=	7.0	Hz),	78.0	(d,	J	C,P	=	4.3	Hz),	71.6	(d,	J	
C,P	=	3.8	Hz),	63.0	(d,	J	C,P	=	5.0	Hz),	63.0	(d,	J	C,P	=	5.0	Hz),	24.7,	19.0	(d,	J	C,P	=	7.9	Hz),	19.0	(d,	
J	 C,P	 =	 7.7	 Hz);	 31P	 NMR	 (162	 MHz,	 DMSO-d6)	 δ	 −2.24;	 HRMS	 (ESI-TOF)	 calcd	 for	C37H33N8O10PH	[M+	H]+	780.2281;	found	780.2296.		








136.3,	116.0,	88.6,	79.2	(d,	J	C,P	=	4.8	Hz),	78.0	(d,	J	C,P	=	3.6	Hz),	73.1	(d,	J	C,P	=	4.0	Hz);	31P	NMR	(162	MHz,	DMSO-d6)	δ	−0.17;	HRMS	 (ESI-TOF)	 calcd	 for	 C9H11N5O7P	 [M	 –	H]−	 332.0407;	found	332.0396.		







α-L-Threofuranosyl	nucleosides	3′-Triphosphates	(3.6a−d).21−23	To	 a	 solution	 containing	 0.1	 mmol	 of	 α-L-threofuranosyl	 nucleosides	 3′-phosphor-2-methylimidazolides	(3.5a−d)	and	2	mL	of	in	anhydrous	DMF	were	added	tributylamine	(0.2	mmol)	and	tributylammonium	pyrophosphate	(0.2	mmol).	The	reaction	mixture	was	then	stirred	 under	 nitrogen	 atmosphere	 for	 8−12	 h	 at	 room	 temperature	with	monitoring	 by	analytical	HPLC.	After	the	reaction	was	finished,	the	reaction	mixture	was	added	dropwise	to	a	stirring	solution	containing	30	mL	of	acetone	and	5	mL	of	saturated	NaClO4	in	acetone.	The	precipitate	was	collected	by	centrifugation	at	4400	rpm	for	15	min	at	room	temperature	and	 dried	 under	 vacuum	 for	 1	 h.	 The	 crude	 precipitate	was	 dissolved	 in	 3	mL	 of	 0.1	M	triethylammonium	 acetate	 buffer	 and	 purified	 by	 a	 semipreparative	 HPLC.	 Fractions	containing	triphosphates	were	collected	and	concentrated,	pH	adjusted	by	triethylamine	to	7.0,	and	lyophilized	to	afford	the	product	as	a	triethylammonium	salt.	The	solid	product	was	resuspended	in	3	mL	of	methanol	and	was	added	dropwise	to	a	solution	containing	40	mL	of	acetone	and	2	mL	of	saturated	NaClO4	in	acetone.	The	solution	was	centrifuged	at	4400	rpm	for	15	min	at	room	temperature.	The	supernatant	was	discarded,	and	the	pellet	was	washed	with	 30	 mL	 of	 acetone	 and	 dried	 under	 vacuum	 for	 1	 h.	 The	 resulting	 white	 solid	 was	
63		





Thermal	Stability	Analysis	of	TNA	Triphosphates.	A	small	volume	(30	μL)	of	4	mM	of	6a−d	in	10	mM	of	Tris	buffer	(pH	8)	was	maintained	at	different	temperatures	(4,	24,	and	37	°C)	for	a	period	of	8	days.	At	specific	time	periods	(1,	5,	 and	8	days),	5	μL	of	 sample	was	 transferred	 to	150	μL	of	HPLC	running	buffer	 [0.1	M	triethylammoniumacetate	 (TEAA)],	 and	 the	 samples	 (50	μL)	were	 analyzed	by	 analytical	reverse-phase	HPLC	with	a	gradient	of	0	to	7%	acetonitrile	in	0.1	M	TEAA	buffer	over	40	min.	Analytical	HPLC	traces	were	analyzed,	and	relative	peak	areas	are	reported	in	Table	2-1.	
Polymerase-Mediated	Primer	Extension.	The	primer	extension	experiment	was	done	in	a	single	PCR	tube	with	100	μL	of	reaction	volume	containing	a	DNA	primer−template	complex	(50	pmol).	The	complex	was	 labeled	with	 an	 IR800	 dye	 at	 the	 5′-end	 of	 the	 DNA	 primer.	 The	 primer−template	 complex	was	annealed	in	1Å~	thermoPol	buffer	(20	mM	Tris·HCl,	0	mM	(NH4)2SO4),	10	mM	KCl,	2	mM	
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MgSO4,	0.1%	Triton	X-100,	pH	8)	by	heating	for	5	min	at	95	°C	and	cooling	for	10	min	at	4	°C.	An	engineered	polymerase,	KOD-RI	(10	μL),	was	pretreated	with	MnCl2	(1	mM)	and	added	to	the	reaction	mixture.	Newly	formed	2.6	a−d	(100	μM)	were	then	added	to	the	reaction	mixture,	 and	 the	 solution	was	 incubated	 for	 3	 h	 at	 55	 °C.	 The	 reaction	was	 analyzed	 by	denaturing	polyacrylamide	gel	electrophoresis.		
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4.2	Abstract	of	the	Chapter	α-L-Threofuranosyl	nucleic	acid	(TNA)	is	an	artificial	genetic	polymer	in	which	the	five-carbon	 ribose	 sugar	 found	 in	RNA	has	been	 replaced	with	 an	 four-carbon	 threose	 sugar.	Despite	 a	 difference	 in	 sugar−phosphate	 backbone,	 TNA	 is	 capable	 of	 forming	 stable	antiparallel	Watson−Crick	duplex	with	complementary	strands	of	DNA	and	RNA	and	itself.	This	property	of	intersystem	base	pairing,	coupled	with	the	chemical	simplicity	of	threose	
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relative	to	ribose,	provides	support	for	the	hypothesis	that	TNA	is	the	potential	candidate	of	RNA	progenitor	in	the	evolution	of	life.	In	an	effort	to	evaluate	the	functional	properties	of	TNA	by	in	vitro	evolution,	engineered	polymerases	have	been	developed	that	are	capable	of	copying	genetic	information	back	and	forth	between	DNA	and	TNA.	However,	the	current	developed	 TNA	 polymerases	 function	 with	 reduced	 activity	 relative	 to	 their	 natural	counterparts,	which	limits	the	evaluation	of	TNA	as	a	primordial	genetic	material.	Here,	we	describe	the	synthesis	of	2′-deoxy-α-L-threofuranosyl	nucleoside	3′-triphosphates	(dtNTPs)	as	 chain-terminating	 substrates	 in	 a	 polymerase-mediated	 TNA	 synthesis	 reaction.	 The	synthesis	of	dtNTPs	should	make	it	possible	to	investigate	the	mechanism	of	TNA	synthesis	by	X-ray	crystallography	by	trapping	the	polymerase	in	the	catalytically	active	conformation.		
4.3	Introduction		TNA	 (α-L-threofuranosyl	 nucleic	 acid)	 is	 an	 artificial	 genetic	 polymer	 developed	 by	Eschenmoser	and	colleagues	as	part	of	an	investigation	into	the	chemical	etiology	of	RNA.1	Unlike	most	 of	 the	 other	RNA	 analogues	 examined	 in	 their	 study,2	 TNA	was	 found	 to	 be	capable	 of	 adopting	 stable	 Watson−Crick	 duplex	 structures	 with	 itself	 and	 with	complementary	 strands	 of	 DNA	 and	 RNA.3	 This	 property	 of	 intersystem	 base	 pairing	provides	a	mechanism	for	 the	 transfer	of	genetic	 information	between	sequential	genetic	polymers	in	the	evolution	of	life.4	In	an	effort	to	broaden	the	concept	of	information	transfer	beyond	 the	 hybridization	 of	 short	 chemically	 synthesized	 oligonucleotides,	 engineered	polymerases	 were	 developed	 to	 replicate	 TNA	 by	 copying	 information	 back	 and	 forth	between	TNA	and	DNA.5,6	These	enzymes	were	used	to	produce	the	first	examples	of	TNA	aptamers	 isolated	by	 in	vitro	selection.7−9	Since	TNA	is	refractory	to	nuclease	digestion,10	
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TNA	 affinity	 reagents	 and	 catalysts	 have	 practical	 value	 in	 diagnostic	 and	 therapeutic	applications	that	require	high	biological	stability.11,12	Detailed	 kinetic	 studies	 measuring	 the	 rate	 of	 TNA	 synthesis	 by	 an	 engineered	 TNA	polymerase	 indicate	 that	 TNA	 synthesis	 occurs	 at	 a	 rate	 that	 is	 vastly	 inferior	 to	 DNA	synthesis	with	natural	DNA	polymerases.13	Insight	into	this	problem	was	recently	obtained	when	the	X-ray	crystal	structure	of	a	laboratory-evolved	TNA	polymerase	was	solved	for	the	apo,	 binary,	 open	 and	 closed	 ternary	 complexes,	 and	 the	 translocated	 product	postcatalysis.14	Analysis	of	the	enzyme	active	site	in	the	closed	ternary	structure	suggests	that	the	slow	rate	of	catalysis	was	due	to	a	suboptimal	binding	geometry	of	the	incoming	TNA	 nucleoside	 triphosphate	 (tNTP).14	 Although	 this	 data	 provided	 a	 key	 piece	 of	information	 that	 could	 be	 used	 as	 a	 framework	 for	 engineering	 new	 TNA	 polymerase	variants,	 solving	 the	 structures	 of	 future	 TNA	 polymerases	 isolated	 along	 the	 same	evolutionary	 trajectory	would	make	 it	 possible	 to	 uncover	 important	 structural	 features	required	to	shape	the	design	of	a	polymerase	active	site	that	is	perfectly	contoured	for	TNA	substrates.	Although	 some	 unnatural	 nucleotide	 triphosphates	 are	 better	 substrates	 for	 DNA	polymerases	 than	 are	 natural	 dNTPs,15	most	 unnatural	 substrates	 function	with	 reduced	activity	relative	to	their	natural	counterparts.16,17	We	therefore	reasoned	that	an	iterative	process	of	directed	evolution	and	X-ray	crystallography	could	provide	valuable	insight	into	the	 general	 principles	 that	 govern	 polymerase	 specificity.18	 While	 our	 polymerase	engineering	endeavors	have	focused	primarily	on	TNA,	information	gained	from	this	process	could	be	applied	 to	other	polymerase	engineering	efforts	 currently	underway	 to	develop	polymerases	that	can	replicate	other	types	of	unnatural	genetic	polymers.19,20	A	critical	step	
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in	this	process	is	to	synthesize	substrates	that	can	trap	the	enzyme	in	the	catalytic	state	of	phosphodiester	bond	formation.	Although	our	previous	efforts	utilized	a	DNA	primer	lacking	a	2′-hydroxyl	group	on	the	terminal	TNA	residue,	this	approach	was	difficult	to	implement	and	often	leads	to	an	open	ternary	structure	that	captures	the	substrate	binding	step	rather	than	the	desired	catalytic	step	observed	in	the	closed	ternary	complex.14	An	 alternative	 approach	 is	 to	 use	 chain-terminating	 nucleoside	 triphosphates	 that	undergo	a	cycle	of	catalysis	prior	to	crystallization.	This	strategy	has	been	used	successfully	to	 capture	 the	 closed	 ternary	 structures	 of	 DNA	 polymerases	 by	 trapping	 the	 second	incoming	 DNA	 nucleoside	 triphosphate	 in	 the	 catalytically	 active	 conformation.21,22	However,	applying	this	approach	to	laboratory-evolved	TNA	polymerases	requires	chemical	synthesis,	as	TNA	substrates	(amidites	and	triphosphates)	are	not	available	commercially.	Here,	 we	 report	 the	 chemical	 synthesis	 of	 2′-deoxy-α-L-threofuranosyl	 nucleoside	 3′-	triphosphates	(dtNTPs)	bearing	the	four	genetic	bases	of	adenine	(A),	cytosine	(C),	guanine	(G),	and	thymine	(T).	The	resulting	substrates	were	obtained	in	eight	chemical	steps	from	advanced	intermediates	described	in	a	previously	published	chemical	synthesis	pathway.23	All	 four	 dtNTPs	 exhibit	 efficient	 site-specific	 chain	 termination	 in	 a	 TNA	 polymerization	reaction	 and	 protein	 crystallization	 studies,	with	 dtATP	 leading	 to	 the	 formation	 of	 high	quality	protein	crystals	that	diffracted	to	2.6−2.8	Å	resolution.			
4.4	Results	and	Discussions	We	 have	 previously	 described	 an	 efficient	 synthesis	 of	4.1a−d,	 which	 involves	 eight	chemical	 transformations	 and	 avoids	 the	 need	 for	 silica	 gel	 purification.23	 This	 strategy	makes	 use	 of	 a	 highly	 efficient	 regioselective	 2′-OH	 protection	 strategy	 developed	 by	
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	We	 began	 by	 selectively	 deprotecting	 the	 2′-benzoyl	 group	 from	 compounds	4.1a−d	using	 a	 1	 N	 NaOH	 solution	 that	 was	 added	 dropwise	 to	 the	 protected	 TNA	 nucleosides	(Scheme	 4-1).	 Nucleosides	4.2a−d	were	 then	 treated	with	 phenyl	 isothiocyanate	 under	basic	 conditions	 to	 synthesize	 2′-phenyl	 isothiocyanate	 derivatives	4.3a−d’,	 which	 were	used	 as	 the	 precursors	 for	 a	 Barton	 deoxygenation	 reaction.	 This	 reaction	 proceeded	efficiently	 for	 each	 nucleoside	 with	 the	 exception	 of	 guanosine	 analogue	 4.2d,	 which	experienced	significant	loss	of	the	diphenylcarbamoyl	(DPC)	group.	To	avoid	the	occurrence	of	a	partially	deprotected	guanine	base,	we	removed	the	DPC	group	prior	to	the	synthesis	of	
4.3d′.27	This	chemical	substitution	enabled	us	to	synthesize	all	four	TNA	nucleosides	as	2′-deoxy	 analogues	 in	 protected	 form.	 Using	 standard	 deoxygenation	 conditions	 with	 α,α′-azobisisobutyronitrile	(AIBN)	as	a	radical	initiator	and	the	tributylstannane	as	the	proton	source	and	 thione	 scavenger,	we	observed	efficient	 conversion	of	4.3a−d′	 to	4.4a−d′	 for	each	 nucleoside,	 except	 protected	 TNA	 cytidine	 derivative	 4.3b.14,26,27	 In	 this	 case,	 the	reaction	 consistently	 produced	 a	 mixture	 of	 compounds	 that	 included	 4.2b	 as	 a	 side	product.28	In	an	effort	to	avoid	this	problem,	we	pursued	milder	reaction	conditions	that	included	the	use	of	triethylborane	and	tris(trimethylsilyl)silane	as	alternative	reagents	for	the	homolytic	deoxygenation	of	the	2′-hydroxyl	group.29,30	Dry	oxygen	was	introduced	into	the	reaction,	which	triggered	a	radical	cascade	and	resulted	in	the	clean	synthesis	of	4.4a−d′	within	30	min	at	room	temperature.	The	 desilylation	 of	 4.4a−d′	 with	 1	 M	 tetrabutylammoniumfluoride	 (TBAF)	 in	 THF	afforded	TNA	nucleoside	derivatives	4.5a−d′	(Scheme	3-2).	To	confirm	that	our	synthesis	strategy	yielded	the	correct	nucleoside	analogue,	the	molecular	structure	of	4.5c	was	solved	
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Although	 numerous	 strategies	 have	 been	 developed	 to	 synthesize	 nucleoside	triphosphates,32−34	we	 chose	 to	 follow	 a	 general	 strategy	 that	 has	worked	 previously	 for	TNA.35	 The	 desired	 dtNTPs	 were	 generated	 from	 activated	 monophosphates	 4.8a−d	 by	displacing	 the	 activated	 2-methylimidazole	 leaving	 group	 with	 pyrophosphate.	 TNA	monophosphates	 4.7a−d	 were	 converted	 to	 their	 3′-phosphoro-2-methylimidazole-activated	 derivatives	 using	 a	 Mitsunobu-like	 reaction	 of	 4.7a−d	 with	 excess	 2-methylimidazole	 and	 triphenylphosphine	 in	 the	 presence	 of	 2,2′-dipyridyl	 disulfide.35	Nucleoside	phosphoro-2-methylimidazolides	(4.8a−d)	were	precipitated	as	a	sodium	salt	with	10	equiv	of	sodium	perchlorate	in	an	ether/acetone	solution.	Compounds	4.8a−d	were	then	converted	to	the	desired	2′-deoxy	nucleoside	triphosphates	4.9a−d	by	treating	4.8a−d	with	tributylammonium	pyrophosphate	and	tributylamine	in	DMF.	The	reaction	progress	of	
4.7a−d,	4.8a−d,	 and	4.9a−d	was	monitored	by	 analytical	HPLC,	 and	 compounds	4.9a−d	were	purified	by	preparative	HPLC.		Next,	we	used	 a	 primer	 extension	 assay	 to	 compare	 the	 ability	 of	 each	2′-deoxy	TNA	triphosphate	to	terminate	TNA	synthesis	on	a	DNA	primer−template	complex	(Figure	4-2).		Primer−template	complexes	T1−T4	were	designed	to	inhibit	TNA	synthesis	midstream	using	one	of	four	chemically	synthesized	dtNTP	substrates	4.9a−d	(Figure	4-2A)	that	would	site-specifically	incorporate	at	a	central	position	in	the	growing	TNA	strand.	In	each	case,	a	5′-IR	labeled	DNA	primer	annealed	to	a	DNA	template	was	incubated	with	Kod-RI	TNA	polymerase	and	the	corresponding	dtNTP	solution	for	60	min	at	55	°C.	Four	different	dtNTP	solutions	were	prepared	in	which	one	of	the	four	normal	tNTP	residues	was	individually	replaced	with	the	corresponding	dtNTP	analogue.	The	chain-terminating	analogues	were	compared	to	the	normal	tNTPs,	which	were	used	as	positive	control	for	the	full-length	product.	An	analysis	of	
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the	resulting	primer	extension	reactions	by	denaturing	polyacrylamide	gel	electrophoresis	revealed	 that	all	 four	dtNTP	substrates	mediate	complete	and	efficient	chain	 termination	during	TNA	synthesis	by	producing	a	truncated	product	at	the	designated	site	in	the	template	(Figure	4-2B).	This	result	shows	that	the	dtNTP	substrates	are	recognized	and	processed	by	a	 laboratory-evolved	 TNA	 polymerase	 to	 produce	 a	 chain-terminated	 TNA	 extension	product.										
Figure	4-2.	Sequence	and	primer	extension	results.	(A) DNA	primer−template	 complexes	were	 used	 to	 assess	 chain	 termination	 efficiency	 of	dtNTP	substrates.	(B)	Primer	extension	experiments	were	performed	using	5′-IR	labeled	DNA	primers	annealed	to	DNA	templates	T1−T4	that	were	incubated	with	the	desired	TNA	triphosphate	solution	and	Kod-RI	TNA	polymerase	for	60	min	at	55	°C.	Reactions	were	quenched	and	analyzed	by	denaturing	polyacrylamide	gel	electrophoresis		(Figure	was	used	with	permission	from	.		J.	Org.	Chem.	2018,	83,	8840−8850.)		 Next,	we	assessed	the	feasibility	of	using	dtNTP	substrates	for	X-ray	crystallography.	A	binary	 complex	 of	 Kod-RI	 TNA	 polymerase	 bound	 to	 a	 primer−template	 duplex	 was	
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General	Information	All	 reactions	 were	 carried	 out	 in	 anhydrous	 solvents	 under	 an	 argon	 or	 nitrogen	atmosphere	 unless	 mentioned	 otherwise.	 All	 reagents	 and	 solvents	 were	 obtained	 from	commercial	 sources	 and	 used	 without	 further	 purification:	 Sublimed	 tetrazole	 in	 dry	acetonitrile	was	 obtained	 from	Glen	Research,	 dibenzyl	 diisopropylphosphoramidite	was	obtained	from	Combi-Blocks,	10%	palladium	on	activated	carbon	(reduced,	dry	powder)	was	obtained	 from	 Strem	 Chemicals,	 and	 5.5	 M	 tert-butyl	 hydroperoxide	 in	 decane	 over	molecular	 sieves	 was	 obtained	 from	 Sigma-Aldrich.	 Hydrogen	 and	 nitrogen	 gases	 were	purchased	as	USP	grade.	Reaction	progress	was	monitored	by	thin	 layer	chromatography	using	 glass-backed	 analytical	 SiliaPlate	 with	 UV-active	 F254	 indicator.	 Flash	 column	chromatography	was	performed	with	SiliaFlash	P60	silica	gel	(40−63	μm	particle	size).	The	
1H,	 13C,	 or	 31P	 nuclear	 magnetic	 resonance	 (NMR)	 spectra	 were	 recorded	 at	 room	temperature	 on	 either	 a	 Bruker	DRX	 400	 or	 500	MHz	 spectrometer	 at	 the	University	 of	California,	Irvine,	NMR	Facility.	The	1H	and	13C	NMR	chemical	shifts	(δ)	are	reported	in	parts	per	million	(ppm)	with	tetramethylsilane	or	deuterium	solvent	as	an	internal	reference.	The	31P	NMR	chemical	shifts	are	proton	decoupled	and	reported	in	parts	per	million	relative	to	an	external	 standard	of	85%	H3PO4.	Peaks	multiplicity	are	designated	with	 the	 following	abbreviations:	s,	singlet;	d,	doublet;	dd,	doublet	of	doublets;	t,	triplet;	m,	multiplet;	br,	broad.	HPLC	analysis	was	performed	on	a	reverse-phase	C18	150	×	4.6	mm2	column	with	5	μm	particle	 size,	 and	 nucleoside	 triphosphates	 were	 purified	 on	 a	 semipreparative	 reverse	phase	C18	250	×	9.4	mm2	column	(Thermo	Scientific,	USA)	using	a	mobile	phase	of	100	mM	triethylammonium	 acetate	 buffer	 (pH	 7.0)/acetonitrile.	 Purified	 molecules	 that	 contain	
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phosphate	 groups	 were	 converted	 into	 their	 corresponding	 Na+	 salt	 using	 the	 Dowex	Marathon	 C	 Na+-form	 of	 resin	 before	 recording	 mass	 spectra.	 High	 resolution	 mass	spectrometry	 (HRMS)	data	were	acquired	using	 the	electrospray	 ionization	 time-of-flight	(ESI-TOF)	method	at	 the	University	 of	California,	 Irvine,	Mass	 Spectrometry	Facility.	The	nucleoside	monophosphates,	 phosphorimidazolides	 and	 triphosphates	were	 dissolved	 in	RNase-free	 water	 with	 10	 mM	 Tris	 pH	 8.0	 and	 quantified	 by	 Nanodrop	 2000	 (Thermo	Scientific,	USA)	using	Beer’s	law.	(T,	ε267:	9600	M−1cm−1.	C,	ε271:	91	00	M−1cm−1.	G,	ε259:	15200	M−1cm−1.	A,	ε259:	15400	M−1cm−1.		
1-(2'-O-Benzoyl-3'-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)-thymine(4.1a).	Product	4.1a	was	prepared	as	described	previously.24	The	crude	product	was	purified	on	silica	gel	with	eluents	(EtOAc/hexane,	from	80	to	100%)	to	afford	the	1-(2′-O-benzoyl-3′-O-






Product	4.1b	was	prepared	as	described	previously.24	The	crude	product	was	purified	on	silica	 gel	with	 eluents	 (EtOAc/CH2Cl2,	 from	20	 to	 35%)	 to	 afford	 the	N4-benzoyl-1-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	 (4.1b)	 as	 a	 white	 solid:	silica	gel	TLC	(hexane/EtOAc,	1:1)	Rf	=	0.35;	1H	NMR	(400	MHz,	CDCl3)	δ	8.25	(d,	1H,	J	=	7.6	Hz),	7.97	(d,	2H,	J	=	7.6	Hz),	7.93	(d,	2H,	J	=	7.6	Hz),	7.64−7.36	(m,	18	H),	6.21	(s,	1H),	5.67	(s,	1H),	4.40	(d,	1H,	J	=	2.4	Hz),	4.17	(d,	1H,	J	=	10	Hz),	4.07	(d,	1H,	J	=	10,	3.2	Hz),	1.07	(s,	3H);	
13C	NMR	(125.8	MHz,	CDCl3)	δ	164.5,	136.0,	135.8,	133.6,	133.3,	132.7,	131.7,	130.4,	130.4,	130.0,	129.2,	129.2,	128.5,	128.1,	128.1,	127.7,	91.4,	82.1,	77.0,	75.8,	27.0,	19.2;	HRMS	(ESI-TOF)	C38H37N3O6SiNa	[M	+	Na]+	682.2349;	found	682.2339.		
N6-Benzoyl-9-(2'-O-benzoyl-3'-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	





threofuranosyl)guanine	(4.1d).	Product	4.1d	was	prepared	as	described	previously.24	The	crude	product	was	purified	using	flash	column	chromatography	on	a	silica	gel	with	eluents	(EtOAc/hexane,	from	80	to	100%)	 to	 afford	 N2-acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)guanine	 (4.1d)	 as	 a	 yellow	 foam:	 silica	 gel	 TLC	(hexane/EtOAc,	1:1)	Rf	=	0.65;	1H	NMR	(400	MHz,	CDCl3)	δ	8.42	(s,	1H),	7.95−7.90	(m,	3H),	7.62−7.55	(m,	5H),	7.44−7.34	(m,	15H),	7.31−7.23	(m,	5H),	6.16	(d,	1H,	J	=	1.2	Hz),	5.81	(s,	1H),	4.57	(m,	1H),	4.22	(dd,	1H,	J	=	12,	7.6	Hz),	4.11	(dd,	1H,	J	=	14.4,	5.6	Hz),	2.50	(s,	3H),	1.03	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	_164.8,	156.5,	154.6,	152.4,	150.4,	142.4,	135.8,	134.0,	132.5,	131.9,	130.5,	130.0,	128.7,	128.1,	120.9,	88.8,	82.5,	76.2,	75.9,	27.0,	25.3,	19.1;	HRMS	(ESI-TOF)	C47H44N6O7SiNa	[M	+	Na]+	855.2938;	found	855.2960.		
1-(3′-O-tert-Butyldiphenylsilyl-α-L-threofuranosyl)	thymine	(4.2a).	To	 a	 solution	 containing	 4.73	 g	 (6.5	 mmol)	 of	 1-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)thymine	(4.1a)	in	12	mL	of	THF	and	5	mL	of	MeOH	at	0	°C	was	added	6.54	mL	(6.5		mmol)	of	ice-cold	1	N	NaOH(aq)	dropwise	while	stirring.	After	15	min,	additional	3.27	mL	(3.3	mmol)	of	ice-cold	1	N	NaOH(aq)	was	added	to	the	reaction	for	an	additional	1	h	of	stirring,	at	which	time	TLC	(hexane/EA,	1:1)	showed	the	complete	consumption	of	the	starting	material,	the	reaction	was	quenched	with	the	dropwise	addition	of	5	mL	of	1	N	HCl(aq)	at	0	°C.	The	solution	was	condensed	to	a	20	mL	volume	under	reduced	pressure,	and	the	crude	product	was	diluted	with	50	mL	of	EtOAc.	The	organic	 layer	was	washed	with	50	mL	of	H2O	and	then	50	mL	of	brine,	dried	over	MgSO4,	and	evaporated	under	
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reduced	pressure.	The	residue	was	purified	on	silica	gel	with	eluents	(MeOH/CH2Cl2,	from	0	to	 5%).	 Product	4.2a	was	obtained	 as	 a	white	 foam:	 yield	2.17	 g	 (72.1%);	 silica	 gel	 TLC	(CH2Cl2/MeOH,	20:1)	Rf	=	0.65;	1H	NMR	(400	MHz,	CDCl3)	δ	10.76	(s,	1H),	7.60	(dd,	2H,	J	=	5.2,	4.0	Hz),	7.59	(d,	1H,	J	=	1.2	Hz),	7.52	(dd,	2H,	J	=	8.0,	1.2	Hz),	7.43−7.41	(m,	1H),	7.39−7.32	(m,	5	H),	5.74	(s,	1H),	5.28	(d,	1H,	J	=	7.2	Hz),	4.39	(s,	1H),	4.28	(d,	1H,	J	=	2	Hz),	4.17	(d,	2H,	J	=	3.2	Hz),	1.87	(s,	3H),	1.01	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	164.9,	151.1,	136.8,	135.8,	132.9,	130.3,	128.1,	109.9,	94.2,	81.5,	77.7,	26.9,	19.1,	12.8;	HRMS	(ESI-TOF)	C25H30N2O5SiNa	[M	+	Na]+	489.1822;	found	489.1822.		
N4-Benzoyl-1-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	(4.2b).	A	stirring	solution	containing	6.8	g	(10.3	mmol)	of	N4-benzoyl-1-(2′-O-benzoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	(4.1b)	in	51	mL	of	THF	and	51	mL	of	MeOH	was	cooled	to	0	°C.	The	solution	was	added	to	10.3	mL	(10.3	mmol)	of	ice-cold	1	N	NaOH(aq)	dropwise	while	stirring.	After	30	min,	another	10.3	mL	(10.3	mmol)	of	ice-cold	1	N	NaOH(aq)	was	added	dropwise	to	the	solution	for	an	additional	30	min	of	stirring,	at	which	time	the	TLC	showed	the	reaction	was	finished;	the	solution	was	quenched	by	adding	10.3	mL	of	1	N	HCl(aq)	 at	 0	 °C.	 The	 crude	 product	was	 condensed	 to	 50	mL	 of	 solution	 under	 reduced	pressure,	and	the	solution	was	poured	into	200	mL	of	EtOAc.	The	organic	layer	was	washed	with	200	mL	of	brine	then	200	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	 The	 crude	 product	was	 purified	 by	 flash	 column	 chromatography	with	 eluents	(MeOH/CH2Cl2,	from	1.6	to	2.5%)	to	afford	N4-benzoyl-1-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	 (4.2b)	 as	 a	 white	 solid:	 yield	 3.84	 g	 (67.1%);	 silica	 gel	 TLC	(MeOH/CH2Cl2,	1:40)	Rf	=	0.45;	1H	NMR	(400	MHz,	CDCl3)	δ	8.19	(d,	1H,	J	=	7.6	Hz),	7.94	(d,	
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2H,	J	=	7.2	Hz),	7.65−7.56	(m,	5H),	7.52−7.48	(m,	4H),	7.44−7.32	(m,	8H),	5.73	(s,	1H),	4.39	(s,	1H),	4.30	(m,	1H),	4.15	(m,	2H),	0.98	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	162.7,	156.0,	145.0,	135.8,	135.7,	133.3,	133.1,	132.9,	132.6,	130.3,	130.2,	129.1,	128.0,	128.0,	127.9,	127.8,	96.4,	95.1,	81.9,	77.1,	26.9,	19.1;	HRMS	(ESI-TOF)	C31H33N3OSiNa	[M	+	Na]+	578.2087;	found	578.2092.		




guanine	(4.2d).	To	 a	 solution	 containing	6.0	 g	 (7.2	mmol)	 of	N2-acetyl-O6-diphenylcarbamoyl-9-(2′-O-benzoyl-α-L-threofuranosyl)	guanine	(4.1d)	in	25	mL	of	THF	and	5	mL	MeOH	at	0	°C	was	added	8.6	mL	of	ice-cold	1	N	NaOH(aq)	dropwise	while	stirring.	After	20	min	of	stirring,	an	additional	4.3	mL	of	ice-cold	1	N	NaOH(aq)	was	added	dropwise	to	the	reaction	for	another	1.5	h	of	stirring,	at	which	TLC	(hexane/EA,	1:1)	showed	the	complete	consumption	of	the	starting	material.	The	solution	was	quenched	by	adding	8	mL	of	1	N	HCl	(aq)	at	0	°C.	The	crude	product	was	condensed	to	15	mL	of	solution	under	reduced	pressure,	and	the	solution	was	poured	into	150	mL	of	EtOAc.	The	organic	layer	was	washed	with	100	mL	of	brine	and	then	100	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	by	flash	column	chromatography	with	eluents	(EtOAc/hexane,	from	25	to	55%	with	5%	CH2Cl2)	to	afford	product	4.2d	as	a	yellow	solid:	yield	3.8	g	(72.4%);	silica	gel	TLC	(EtOAc/CH2Cl2,	2:1)	Rf	=	0.33;	1H	NMR	(400	MHz,	CDCl3)	δ	8.46	(s,	1H),	8.26	(s,	1H),	7.58	(d,	4H,	J	=	6.4	Hz),	7.41−7.30	(m,	14H),	7.25−7.23	(m,	2H),	5.86	(s,	1H),	4.56	(s,	1H),	4.41	(s,	1H),	3.97	(m,	2	H),	2.18	(s,	3H),	1.00	(s,	9H);	13C	NMR	(125.8	MHz,	CD3OD)	δ	156.1,	154.2,	151.6,	150.7,	142.4,	135.9,	135.8,	133.2,	132.6,	130.1,	129.4,	128.0,	128.0,	121.6,	92.3	82.5,	77.3,	 74.9,	 27.0,	 25.1,	 19.2;	 HRMS	 (ESI-TOF)	 C40H40N6O6SiNa	 [M	 +	 Na]+	 751.2676;	 found	751.2681.	
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N2-Acetyl-9-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)-guanine	(4.2d′).		To	a	cooled	solution	of	27	mL	of	20%	trifluoroacetic	acid	in	CH2Cl2	was	added	3.59	g	(4.9	mmol)	 of	 N2-acetyl-O6-diphenylcarbamoyl-9-(3′	 -O-	 tert-butyldiphenylsilyl	 -α-L	 -	threofuranosyl)guanine	(4.2d),	and	it	was	stirred	at	0	°C	for	1	h.	The	reaction	mixture	was	evaporated	to	dryness	under	reduced	pressure,	and	the	resulting	crude	product	was	purified	by	silica	gel	column	chromatography	with	eluents	(MeOH/CH2Cl2)	to	afford	N2-acetyl-9-	(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)guanine	 (4.2d′)	 as	 a	 pale-yellow	 solid:	 yield	2.4	g	(77%);	TLC	(MeOH/CH2Cl2,	1:10)	Rf	=	0.45;	1H	NMR	(400	MHz,	CDCl3)	δ	12.07	(s,	1H),	9.27	(s,	1H),	8.30	(s,	1H),	7.59−7.53	(m,	3H),	7.45−7.34	(m,	6H),	7.26	(d,	2H,	J	=	8	MHz),	6.09	(s,	1H),	4.57	(s,	1H),	4.01−3.99	(m,	1H),	2.47−2.44	(m,	1H),	2.28	(s,	3H),	1.02	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	172.1,	148.4,	147.6,	138.5,	136.1,	133.2,	133.1,	130.6,	130.5,	128.4,	128.3,	121.6,	84.3,	80.0,	72.5,	41.5,	27.2,	24.9,	19.3;	HRMS	(ESI-TOF)	C27H31N5O5SiNa	[M	+	Na]+	556.1992;	found	556.2003.		
1-(2′-O-Phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)		
thymine	(4.3a).	To	 a	 solution	 containing	 3.72	 g	 (8.0	 mmol)	 of	 1-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)thymine	(4.2a)	and	0.52	g	(21.8	mmol)	of	NaH	in	60	mL	of	anhydrous	THF		was	added	dropwise	1.40	mL	(11.3	mmol)	of	phenyl	 isothiocyanate,	and	the	mixture	was	stirred	for	1.5	h	in	room	temperature.	When	TLC	(hexane/EtOAc,	3:2)	showed	the	reaction	was	completed,	the	reaction	was	quenched	with	the	addition	of	10	mL	of	water	at	0	°	C.	The	volatile	solution	was	evaporated	under	reduced	pressure,	and	the	residue	was	dissolved	in	
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100	mL	of	EtOAc.	The	organic	layer	was	washed	with	200	mL	of	brine	and	then	200	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	residue	was	purified	on	silica	gel,	eluting	with	60−80%	EtOAc	in	hexane	in	steps	of	5%	increase	in	EtOAc	for	every	200	mL.	 Product	4.3a	was	 obtained	 as	 a	 white	 solid:	 yield	 4.01	 g	 (83%);	 silica	 gel	 TLC	(hexane/EtOAc,	 1:1)	 Rf	 =	 0.35;	 1H	 NMR	 (400	 MHz,	 CDCl3)	 δ	 9.47	 (s,	 1H),	 7.67	 (m,	 5H),	7.51−7.34	(m,	6H),	7.25−7.24	(m,	2H),	7.12−7.02	(m,	1H),	6.08	(s,	1H),	5.92	(s,	1H),	4.45	(s,	1H),	4.05	(d,	1H,	J	=	10	Hz),	3.84	(m,	1H),	3.78	(m,	1H),	1.86	(s,	3H),	1.10	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	164.2,	150.7,	 136.0,	 135.7,	 132.8,	 130.4,	 129.0,	 126.0,	 128.1,	 111.4,	89.5,75.0,	 27.0,	 19.3,	 12.5;	HRMS	 (ESI-TOF)	 C32H35N3O5SSiNa	 [M	 +	Na]+	 624.1964;	 found	624.1959.	
N4-Benzoyl-1-(2′-O-phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-
threofuranosyl)cytosine	(4.3b).	To	 a	 stirring	 solution	 containing	 2.60	 g	 (4.7	 mmol)	 of	 N4-benzoyl-1-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	(4.2b)	and	319	mg	(12.6	mmol)	of	NaH	in	47	mL	of	anhydrous	THF	was	added	dropwise	813	μL	(6.6	mmol)	of	phenyl	isothiocyanate	at	0	°C.	The	reaction	was	stirring	at	room	temperature	for	1.5	h,	at	which	time	the	TLC	shows	that	the	reaction	was	finished.	The	mixture	was	quenched	slowly	at	0	°C	by	adding	dropwise	2	mL	of	water	followed	by	8	mL	of	1	N	HCl(aq).	The	crude	mixture	was	condensed	to	20	mL	of	solution	under	reduced	pressure,	and	the	solution	was	poured	into	200	mL	of	EtOAc.	The	organic	layer	was	washed	with	200	mL	of	brine	and	then	200	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	by	flash	column	chromatography	with	eluents	(EtOAc/CH2Cl2,	from	13	to	25%)	to	afford	product	4.3b	as	a	white	solid:	yield	3.1	g	(95.9%);	silica	gel	TLC	(EtOAc/CH2Cl2,	1:4)	Rf	=	0.4;	1H	NMR	(400	
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MHz,	CDCl3)	δ	8.24	(d,	1H,	J	=	6.8	Hz),	7.93	(d,	2H,	J	=	7.6	Hz),	7.64−7.26	(m,	18H),	7.13	(t,	1H,	
J	=	7.2	Hz),	5.99	(s,	1H),	4.50	(d,	1H,	J	=	2.4	Hz),	4.12	(d,	1H,	J	=	10	Hz),	1.04	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	165.0,	152.8,	151.8,	149.6,	141.9,	135.9,	135.7,	133.7,	132.7,	132.5,	131.7,	130.3,	 128.8,	 128.1,	 128.0,	 126.1,	 123.0,	 87.9,	 75.3,	 29.7,	 26.9,	 19.1;	 HRMS	 (ESI-TOF)	C38H38N4O5SSiNa	[M	+	Na]+	713.2230;	found	713.2205.		
N6-Benzoyl-9-(2′-O-phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-
threofuranosyl)adenine	(4.3c).	To	 a	 stirring	 solution	 containing	 3.3	 g	 (5.69	 mmol)	 of	 N6-benzoyl-9-(3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	(4.2c)	and	368	mg	(15.36	mmol)	of	NaH	in		57	mL	of	anhydrous	THF	was	added	dropwise	917	μL	(7.40	mmol)	of	phenyl	isothiocyanate	at	0	°C.	The	reaction	was	stirred	at	room	temperature	for	1.5	h,	at	which	time	the	TLC	shows	that	the	reaction	was	finished.	The	mixture	was	quenched	slowly	at	0	°C	by	adding	dropwise	3	mL	of	water	followed	by	10	mL	of	1	N	HCl(aq).	The	crude	mixture	was	condensed	to	30	mL	of	solution	under	reduced	pressure,	and	the	solution	was	poured	into	200	mL	of	EtOAc.	The	organic	layer	was	washed	with	200	mL	of	brine	and	then	200	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	with	flash	column	chromatography	with	eluents	(EtOAc/CH2Cl2,	from	13	to	25%)	to	afford	4.3c	as	a	yellowish	solid:	yield	3.72	g	(91.4%);	silica	gel	TLC	(EtOAc/CH2Cl2,	1:4)	Rf	=	0.45;	1H	NMR	(400	MHz,	CDCl3)	δ	8.71	(s,	1H),	8.59	(s,	1H),	8.00	(d,	2H,	J	=	6.8	Hz),	7.65−7.04	(m,	18H),	6.37	(s,	2H),	4.58	(s,	1H),	4.13	(s,	1H),	3.94	(s,	1H),	1.07	(s,	9H);	 13C	NMR	(100.6	MHz,	CDCl3)	δ	165.0,	152.8,	151.8,	149.6,	141.9,	135.9,	135.7,	133.7,	132.7,	132.5,	131.7,	130.3,	128.8,	128.1,	128.0,	
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126.1,	 123.0,	 87.9,	 75.3,	 29.7,	 26.9,	 19.1;	 HRMS	 (ESI-TOF)	 C39H38N6O4SSiNa	 [M	 +	 Na]+	737.2343;	found	737.2358.		
N2-Acetyl-9-(2′-O-phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-
threofuranosyl)guanine	(4.3d′).		To	a	solution	containing	1.32	g	(2.5	mmol)	of	4.2d′	and	0.27	g	(6.7	mmol)	of	NaH	in	20	mL	of	anhydrous	THF	was	added	dropwise	0.37	mL	(2.9	mmol)	of	phenyl	isothiocyanate,	and	the	mixture	 was	 stirred	 for	 1.5	 h	 at	 room	 temperature.	When	 TLC	 (MeOH/CHCl3,	 1:10)	showed	the	complete	consumption	of	starting	material,	the	reaction	was	quenched	with	the	addition	of	10	mL	of	water.	The	volatile	solution	was	evaporated	under	reduced	pressure,	and	the	residue	was	dissolved	in	100	mL	of	EtOAc.	The	organic	layer	was	washed	with	200	mL	 of	 brine	 and	 then	 200	mL	 of	H2O,	 dried	 over	MgSO4,	 and	 evaporated	 under	 reduced	pressure.	The	residue	was	purified	by	silica	gel	chromatography	with	eluents	(MeOH/DCM,	from	0	to	6%)	to	afford	the	product	4.3d′	as	a	pale-yellow	solid:	yield	920	mg	(57%);	silica	gel	TLC	(CH2Cl2/MeOH,	10:1)	Rf	=	0.65;	1H	NMR	(400	MHz,	CDCl3)	δ	12.33−11.91	(m,	1H),	9.74	(s,	1H),	8.23−8.16	(m,	1H),	7.57	(m,	5H),	7.41−7.25	(m,	7H),	7.20−7.17	(m,	2H),	7.06	(s,	1H),	6.50	(s,	1H),	3.79	(s,	1H),	3.75−3.72	(m,	2H),	2.16	(d,	3H,	J	=	12	Hz),	0.93	(d,	9H,	J	=	18	Hz);	 13C	NMR	(100.6	MHz,	CDCl3)	δ	156.1,	148.6,	147.9,	137.9,	135.9,	135.7,	132.5,	131.8,	130.2,	129.8,	129.0,	128.0,	127.8,	125.3,	122.8,	121.4,	115.2,	88.8,	87.5,	77.3,	75.5,	26.9,	26.8,	24.2,	19.0;	HRMS	(ESI-TOF)	C34H36N6O5SSiNa	[M	+	Na]+	691.2135;	found	691.2120.		
1-(2′-Deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)thymine	(4.4a).	
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1-(2′-O-Phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)	thymine	 (4.3a)	was	 coevaporated	 twice	with	 3	mL	 of	 anhydrous	 toluene	 under	 reduced	pressure	and	dried	overnight	under	vacuum.	To	a	solution	of	1.09	g	(2.1	mmol)	of	4.3a	in	15	mL	 of	 anhydrous	 toluene	 was	 added	 2.08	 mL	 (5.4	 mmol)	 of	 tris(trimethylsilyl)silane	followed	by	2.6	mL	of	triethylborane	(1	M	in	THF)	under	an	argon	atmosphere.	The	reaction	was	 flushed	 with	 dry	 air	 several	 times,	 and	 the	 resulting	 mixture	 was	 stirred	 at	 room	temperature	 for	 45	 min.	 When	 TLC	 (CH2Cl2/MeOH,	 10:1)	 showed	 the	 reaction	 to	 be	complete,	the	reaction	was	quenched	with	the	addition	of	7	mL	of	water.	The	solvent	was	evaporated	under	reduced	pressure,	and	the	residue	was	then	purified	by	silica	gel	column	chromatography	eluent	(MeOH/CH2Cl2,	from	0	to	8%)	to	afford	the	product	4.4a:	yield	760	mg	(77.8%);	silica	gel	TLC	(CH2Cl2/MeOH,	20:1)	Rf	=	0.65;	1H	NMR	(400	MHz,	CDCl3)	δ	8.48	(s,	1H),	7.70	(d,	1H,	J	=	1.2	Hz),	7.63	(dd,	2H,	J	=	9.2,	6.8	Hz),	7.55	(dd,	2H,	J	=	9.6,	6.4	Hz),	7.46−7.36	(m,	6H),	6.12	(dd,	1H,	J_	_=	10,	5.6	Hz),	4.47−4.35	(m,	1H),	4.14	(m,	1H),	3.75	(dd,	1H,	J	=	13.6,	6.2	Hz),	2.43−2.36	(m,	1H),	2.12	(d,	1H,	J	=	16	Hz),	1.93	(d,	3H,	J	=	1.2	Hz),	1.61	(s,	1H),	1.05	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	164.0,	150.5,	136.7,	135.8,	133.0,	130.8,	128.1,	110.3,	86.1,	77.6,	72.3,	41.8,	27.0,	19.2,	12.8;	HRMS	(ESI-TOF)	C25H30N2O4SiNa	[M	+	Na]+	473.1873;	found	473.1868.		
N4-Benzoyl-1-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	
(4.4b).	
N4-Benzoyl-1-(2′-O-phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L	threofuranosyl)cytosine	(3.3b)	was	coevaporated	with	10	mL	of	anhydrous	toluene	twice	under	 reduced	 pressure.	 To	 a	 solution	 containing	 2.0	 g	 (2.9	mmol)	 of	4.3b	 in	 58	mL	 of	
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anhydrous	toluene	was	added	2.18	mL	(7.3	mmol)	of	trimethylsilylsilane	followed	by	adding	dropwise	3.48	mL	(3.48	mmol)	of	triethylborane	(1	M	in	THF)	under	an	argon	atmosphere.	The	reaction	was	flushed	with	dry	air	several	times,	and	the	resulting	mixture	was	stirred	at	room	temperature	for	30	min.	When	TLC	showed	that	the	reaction	was	finished,	the	crude	solution	was	brought	to	150	mL	with	EtOAc,	washed	with	200	mL	of	brine	and	then	200	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	 by	 flash	 column	 chromatography	with	 eluents	 (MeOH/CH2Cl2,	 from	1	 to	 3%)	 to	afford	4.4b	as	a	white	solid:	yield	1.21	g	(77.4%);	silica	gel	TLC	(MeOH/CH2Cl2,	1:40)	Rf	=	0.28;	1H	NMR	(400	MHz,	CDCl3)	δ	8.27	(d,	1H,	J	=	7.6	Hz),	7.94	(d,	2H,	J	=	7.2	Hz),	7.60−7.57	(m,	4H),	7.51−7.48	(m,	4H),	7.45−7.33	(m,	6H),	6.13	(d,	1H,	J	=	5.6	Hz),	4.47	(s,	1H),	4.23	(d,	1H,	J	=	10	Hz),	3.91	(dd,	1H,	J	=	10,	3.6	Hz),	2.39	(m,	2H)	0.99	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	162.3,	145.3,	135.7,	135.6,	133.1,	132.8,	132.6,	130.1,	130.1	129.0,	128.0,	127.9,	127.7,	 96.0,	 88.4,	 78.5,	 72.2,	 42.0,	 26.8,	 18.9;	HRMS	 (ESI-TOF)	C31H33N3O4SiNa	 [M	+	Na]+	562.2138;	found	562.2142.		
N6-Benzoyl-9-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	
(4.4c).	
N6-Benzoyl-9-(2′-O_-phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	(4.3c)	was	coevaporated	with	10	mL	of	anhydrous	 toluene	 twice	under	 reduced	 pressure.	 To	 a	 solution	 containing	 1.8	 g	 (2.5	mmol)	 of	4.3c	 in	 25	mL	 of	anhydrous	toluene	was	added	1.95	mL	(6.3	mmol)	of	trimethylsilylsilane	followed	by	adding	dropwise	3.02	mL	(3.0	mmol)	of	triethylborane	(1	M	in	THF)	under	an	argon	atmosphere.	The	reaction	was	flushed	with	dry	air	several	times,	and	the	resulting	mixture	was	stirred	at	
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room	temperature	for	30	min.	When	TLC	showed	that	the	reaction	was	finished,	the	crude	solution	was	poured	into	150	mL	of	EtOAc,	washed	with	200	mL	of	brine	and	then	200	mL	of	H2O,	dried	over	MgSO4,	and	evaporated	under	reduced	pressure.	The	crude	product	was	purified	 by	 flash	 column	 chromatography	with	 eluents	 (MeOH/CH2Cl2,	 from	1	 to	 3%)	 to	afford	product	4.4c	as	a	white	solid:	yield	1.12g	(78.9%);	silica	gel	TLC	(MeOH/CH2Cl2,	1:40)	Rf	=	0.3;	1H	NMR	(400	MHz,	CDCl3)	δ	9.65	(s,	1H),	8.74	(s,	1H),	8.57	(s,	1H),	8.00	(d,	2H,	J	=	7.2	Hz),	7.56	(d,	2H,	J	=	7.2	Hz),	7.51−7.27	(m,	11H),	6.41	(d,	1H,	J	=	6.8	Hz),	4.58	(s,	1H),	4.12	(d,	1H,	J	=	9.6	Hz),	3.90	(dd,	1H,	J	=	9.6,	3.6	Hz),	2.54	(m,	2H),	0.95	(s,	9H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	164.9,	152.3,	151.4,	149.4,	135.5,	135.4,	133.7,	132.6,	132.4,	130.0,	128.6,	127.8,	127.8,	123.3,	84.6,	77.1,	72.1,	41.3,	26.7,	18.7;	HRMS	(ESI-TOF)	C32H33N5O3SiNa	[M	+	Na]+	586.2250;	found	586.2251.		
N2-Acetyl-9-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)guanine	
(4.4d′).		
N2-Acetyl-9-(2′-O-phenylthioxocarbamoyl-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)guanine	(4.3d′)	was	co-evaporated	twice	with	3	mL	of	anhydrous	toluene	under	 reduced	pressure	 and	dried	 overnight	 under	 vacuum.	To	 a	 solution	 of	 0.82	 g	 (1.3	mmol)	 of	 4.3d′	 in	 15	 mL	 of	 anhydrous	 toluene	 was	 added	 1.3	 mL	 (3.1	 mmol)	 of	tris(trimethylsilyl)silane	followed	by	1.5	mL	of	triethylborane	(1	M	in	THF)	under	an	argon	atmosphere.	The	reaction	was	flushed	with	dry	air	several	times,	and	the	resulting	mixture	was	stirred	at	room	temperature	for	45	min,	at	which	time	TLC	(CH2Cl2/MeOH,	10:1)	showed	the	reaction	to	be	complete.	The	reaction	was	quenched	with	the	addition	of	3	mL	of	water.	The	volatile	solution	was	evaporated	under	reduced	pressure,	and	the	crude	product	was	
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purified	by	silica	gel	column	chromatography	with	eluents	(MeOH/CH2Cl2,	from	0	to	7%)	to	afford	the	product		4.4d’	as	a	white	solid:	yield	540	mg	(83.2%);	silica	gel	TLC	(CH2Cl2/MeOH,	20:1)	Rf	=	0.55;	1H	NMR	(400	MHz,	CDCl3)	δ	11.88	(s,	1H),	9.09	(s,	1H),	8.11	(s,	1H),	7.43−7.37	(m,	4H),	7.26−7.19	(m,	7	H),	7.17−7.07	(m,	1H),	5.91	(dd,	1H,	J	=	7.6,	3.2	Hz),	4.38	(s,	1H),	3.82	(d,	1H,	J	=	8	Hz),	3.66	(dd,	1H,	J	=	11.6,	4.0	Hz),	2.28−2.26	(m,	1H),	2.09	(s,	3H),	0.84	(s,	9H);	
13C	NMR(125.8	MHz)	δ	171.8,	148.2,	147.3,	138.2,	135.8,	132.9,	130.3,	128.1,	121.3,	84.1,	72.3,	 41.3,	 27.0,	 24.6,	 19.1;	 HRMS	 (ESI-TOF)	 C27H31N5O4SiNa	 [M	 +	 Na]+	 540.2064;	 found	540.2064.		
1-(2′-Deoxy-α-L-threofuranosyl)thymine	(4.5a).	To	 a	 cold	 solution	 (0−5	 °C)	 of	 750	 mg	 (1.6	 mmol)	 of	 1-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)thymine	(4.4a)	in	12	mL	of	THF	was	added	dropwise	1.9	mL	(1.9	mmol)	of	tetrabutylammonium	fluoride	(1	M	solution	in	THF),	and	the	mixture	was	stirred	for	2	h	at	0−5	°C.	The	solvent	was	evaporated	under	reduced	pressure,	and	the	crude	 product	 was	 purified	 by	 silica	 gel	 column	 chromatography	 with	 eluents	(MeOH/CH2Cl2,	 from	 0	 to	 12%).	 1-(2′-Deoxy-α-L-threofuranosyl)thymine	 (4.5a)	 was	obtained	as	a	white	solid:	yield	305	mg	(86.3%);	silica	gel	TLC	(CH2Cl2/MeOH,	10:1)	Rf	=	0.35;	1H	NMR	(400	MHz,	DMSO-d6)	δ	6.89	(s,	1H),	5.18	(dd,	1	H,	J	=	8.4,	4.8	Hz),	3.50	(s,	1H),	3.13	(d,	1H,	J	=	7.6	Hz),	2.91	(dd,	1H,	J	=	10.4,	4.4	Hz),	1.64−1.60	(m,	2H),	1.02	(d,	1H,	J	=	11.6	Hz),	0.91	(s,	3H);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	163.9,	150.5,	137.1,	108.5,	84.6,	76.3,	68.8,	40.07,	12.3;	HRMS	(ESI-TOF)	C9H12N2O4Na	[M	+	Na]+	235.0797;	found	235.0791.		
N4-Benzoyl-1-(2′-deoxy-α-L-threofuranosyl)	cytosine	(4.5b).	
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To	a	cold	solution	(0−5	°C)	containing	1.2	g	(2.2	mmol)	of	N4-benzoyl-1-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)cytosine	 (4.4b)	 in	 22	 mL	 of	 THF	 was	 added	dropwise	6.7	mL	(6.7	mmol)	of	 tetrabutylammonium	fluoride	(1	M	solution	 in	THF).	The	mixture	was	stirred	for	4	h	at	0	°C.	The	solvent	was	evaporated	under	reduced	pressure,	and	the	 crude	 product	 was	 purified	 by	 flash	 column	 chromatography	 with	 eluents	(MeOH/CH2Cl2,	 from	2	to	5%).	Product	4.5b	was	obtained	as	a	white	solid:	yield	650	mg	(97.0%);	silica	gel	TLC	(MeOH/CH2Cl2,	1:20)	Rf	=	0.31;	1H	NMR	(400	MHz,	CDCl3)	δ	8.08	(d,	1H,	J	=	7.6	Hz),	7.88	(d,	2H,	J	=	8.0	Hz),	7.58	(t,	1H,	J	=	7.2	Hz),	7.50−7.43	(m,	3H),	6.00	(d,	1H,	
J	=	6.8	Hz),	4.63	(m,	1H),	4.34	(d,	1H,	J	=	10	Hz),	4.11	(dd,	1H,	J	=	10,	3.6	Hz),	2.72	(d,	1H,	J	=	14.8	Hz),	2.47	(m,	1H);	13C	NMR	(125.8	MHz,	CDCl3)	δ	168.9,	164.6,	157.9,	147.1,	134.7,	134.0,	129.8,	129.0,	97.5,	90.0,	79.4,	71.0,	42.3;	HRMS	(ESI-TOF)	C15H15N3O4Na	[M	+	Na]+	324.0960	;	found	324.0972.	
N6-Benzoyl-9-(2′-deoxy-α-L-threofuranosyl)	adenine	(4.5c).	To	a	cold	solution	(0−5	°C)	containing	1.3	g	(2.3	mmol)	of	N6-benzoyl-9-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)adenine	 (4.4b)	 in	 23	 mL	 of	 THF	 was	 added	dropwise	4.6	mL	(4.6	mmol)	of	 tetrabutylammonium	fluoride	(1	M	solution	 in	THF).	The	mixture	was	stirred	for	4	h	at	0	°C.	The	solvent	was	evaporated	under	reduced	pressure,	and	the	 crude	 product	 was	 purified	 by	 flash	 column	 chromatography	 with	 eluents	(MeOH/CH2Cl2,	 from	2	 to	 4%)	 to	 afford	 the	product	4.5b	as	 a	white	 solid:	 yield	678	mg	(90.3%);	silica	gel	TLC	(MeOH/CH2Cl2,	1:20)	Rf	=	0.28;	1H	NMR	(400	MHz,	CDCl3)	δ	8.72	(d,	2H,	J	=	3.6	Hz),	8.09	(d,	2H,	J	=	7.6	Hz),	7.66	(t,	1H,	J	=	7.6	Hz),	7.57	(t,	2H,	J	=	7.6	Hz),	6.53	(dd,	1H,	J	=	8.0,	1.6	Hz),	4.62	(t,	1H,	J	=	4.4	Hz),	4.20	(d,	1H,	J	=	9.6	Hz),	4.10	(dd,	1H,	J	=	9.6,	4.0	Hz),	2.78	(m,	1H),	2.49	(d,	1H,	 J	=	14.8	Hz);	 13C	NMR	(125.8	MHz,	CD3OD)	δ	168.1,	153.0,	
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151.0,	 145.0,	 135.0,	 133.9,	 129.8,	 129.4,	 125.1,	 86.2,	 78.6,	 71.3,	 41.8;	 HRMS	 (ESI-TOF)	C16H15N5O3Na	[M	+	Na]+	348.1073;	found	348.1076.	
	
N2-Acetyl-9-(2′-deoxy-α-L-threofuranosyl)guanine	(4.5d′).		To	 a	 cold	 solution	 (0−5	 °C)	 of	 530	mg	 (1.0	mmol)	 of	N2-acetyl-9-(2′-deoxy-3′-O-tert-butyldiphenylsilyl-α-L-threofuranosyl)guanine	(4.4d’)	in	12	mL	of	THF	was	added	dropwise	1.3	mL	(1.3	mmol)	of	tetrabutylammonium	fluoride	(1	M	solution	in	THF),	and	the	mixture	was	stirred	for	1	h	at	0−5	°C.	The	solvent	was	evaporated	under	reduced	pressure,	and	the	resulting	 crude	 product	 was	 purified	 by	 silica	 gel	 column	 chromatography	 with	 eluents	(MeOH/CH2Cl2,	from	0	to	10%)	to	afford	the	product	4.5d’	as	a	white	solid:	yield	220	mg	(77%);	silica	gel	TLC	(CH2Cl2/MeOH,	10:1)	Rf	=	0.35;	1H	NMR	(400	MHz,	DMSO-d6)	δ	11.14	(s,	 1H),	 10.83	 (s,	 1H),	 7.32	 (s,	 1H),	 5.24	 (dd,	 1H,	 J	=	10,	 6	Hz),	 4.52	 (s,	 1H),	 3.62	 (s,	 1H),	3.08−3.07	(m,	2H),	1.77−1.73	(m,	1H),	1.41−1.37	(m,	1H),	1.29	(s,	3H);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	173.5,	154.9,	148.2,	147.8,	138.2,	119.9,	83.3,	76.5,	69.0,	40.3,23.8;	HRMS	(ESI-TOF)	C11H13N5O4Na	[M	+	Na]+	302.0865;	found	302.0854.		
General	Procedure	A	for	the	Preparation	of	4.6a-d′.		To	a	suspension	of	4.5a−d’	 in	sublimed	tetrazole	in	anhydrous	acetonitrile	(1.8	equiv,	0.45	M)	was	added	(BnO)2PN(i-Pr)2	(1.3	equiv),	and	the	reaction	mixture	stirred	at	room	temperature	for	1	h.	The	reaction	mixture	was	cooled	to	0	°C,	treated	with	30%	H2O2	in	water	(3−10	 equiv),	 and	 stirred	 for	 an	 additional	 30	 min.	 The	 reaction	 mixture	 was	 then	evaporated	under	reduced	pressure	and	purified	by	silica	gel	chromatography.	
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1-(2′-Deoxy-α-L-threofuranosyl)thymine-3′-dibenzylmonophosphate	(4.6a).	General	procedure	A	was	used	with	the	following:	1.00	g	(4.7	mmol)	of	4.5a,	20	mL	(9	mmol)	 of	 tetrazole,	 1.80	 g	 (5.18	 mmol)	 of	 (BnO)2PN(i-Pr)2,	 and	 2	 mL	 of	 H2O2.	Characterization	 included	 the	 following:	 column	 chromatography	 with	 eluents	(EtOAc/MeOH,	100−98/2−95/5%);	yield	1.95	g	(87%);	silica	gel	TLC	(MeOH/CH2Cl2,	1:20)	Rf	=	0.55;	1H	NMR	(400	MHz,	CDCl3)	δ	7.36−7.26	(m,	10	H),	6.09	(d,	1H,	J	=	8.6	Hz),	5.04−4.94	(m,	4H),	4.28	(m,	1H),	3.85	(d,	1H,	J	=	12.6	Hz),	2.48	(m,	1H),	2.16	(d,	1H,	J	=	15.6	Hz),	1.79	(s,	3H);	13CNMR	(125.8	MHz,	CDCl3)	δ	135.9,	129.1,	128.9,	128.2,	110.4,	85.5,	77.5	(d,	J	C,P	=	6.4	Hz),	76.9,	75.3	(d,	J	C,P	=	7.4	Hz),	70.0	(d,	J	C,P	=	5.9	Hz),	39.7,	12.7;	31P	NMR	(162	MHz,	CDCl3)	
δ	0.65;	HRMS	(ESI-TOF)	C23H25N2O7PNa	[M	+	Na]+	495.1297;	found	495.1299.		
N4-Benzoyl-1-(2′-deoxy-α-L-threofuranosyl)cytosine-3′-dibenzyl-monophosphate	
(4.6b).	General	procedure	A	was	used	with	the	following:	300	mg	(1.0	mmol)	of	4.5b,	4	mL	(1.8	mmol)	of	tetrazole	in	acetonitrile,	316	μL	(1.3	mmol)	of	(BnO)2PN(i-Pr)2,	and	2	mL	of	H2O2.	Characterization	 included	 the	 following:	 silica	 gel	 chromatography	 with	 eluents	(MeOH/CH2Cl2,	from	1.0	to	2.5%);	yield	410	mg	(73.3%);	silica	gel	TLC	(MeOH/CH2Cl2,	1:40)	Rf	 =	0.33;	 1H	NMR	 (400	MHz,	CD3OD)	δ	8.07	 (d,	 1H,	 J	=	7.2	Hz),	 7.93	 (d,	 1H,	 J	=	6.8	Hz),	7.65−7.61	(m,	1H),	7.53	(m,	3H),	7.32−7.25	(m,	11H),	6.03	(d,	1H,	J	=	6.4	Hz),	5.05	(s,	1H),	4.96−4.88	(m,	4H),	4.42	(d,	1H,	J	=	10.8	Hz),	4.14	(d,	1H,	J	=	10.8	Hz),	2.63−2.49	(m,	2H);	13C	NMR	(125.8	MHz,	CD3OD)	δ	168.9,	164.7,	157.7,	146.0,	136.9	(d,	J	C,P	=	6.2	Hz),	136.7	(d,	J	C,P	=	5.9	Hz),	134.7,	134.0,	129.8,	129.8,	129.7,	129.7,	129.2,	129.1,	129.1,	97.8,	89.8,	78.8	(d,	J	C,P	=	5.4	Hz),	77.5	(d,	J	C,P	=	6.4	Hz),	71.1	(d,	J	C,P	=	6.0	Hz),	70.9	(d,	J	C,P	=	5.9	Hz),	40.8	(d,	J	C,P	=	3.8	
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Hz);	 31P	 NMR	 (162	 MHz,	 CD3OD)	 δ	 −1.48;	 HRMS	 (ESI-TOF)	 C29H28N3O7PNa	 [M	 +	 Na]+	584.1563;	found	584.1561.		
N6-Benzoyl-9-(2′-deoxy-α-L-threofuranosyl)adenine-3′-dibenzyl-monophosphate	





General	Procedure	B	for	the	Preparation	of	4.7a−d.	Trialkyl	monophosphates	4.6a−d	were	dissolved	in	methanol	and	purged	with	nitrogen	gas	three	times.	The	solution	was	added	to	0.1−0.2	mass	equivalent	of	10%	Pd/C	and	repurged	with	nitrogen	gas,	followed	by	hydrogen	gas.	The	mixture	was	stirred	at	room	temperature	for	1−2	h	under	hydrogen	gas,	at	which	time	TLC	showed	that	the	reaction	was	finished.	The	reaction	was	purged	with	nitrogen	gas	three	times	and	poured	on	a	pad	of	Celite	for	filtration.	The	 filtrate	was	 collected	and	evaporated	under	 reduced	pressure	 to	dryness.	The	 crude	product	was	added	to	15	mL	of	30%	NH4OH	for	deprotection	at	37	°C	for	18	h.	The	mixture	was	cooled	to	room	temperature,	and	the	solvent	was	evaporated	to	dryness.	The	residue	was	resuspended	 in	3	mL	of	methanol	at	40	°C	with	stirring,	and	the	solution	was	added	dropwise	 to	 40	 mL	 of	 acetone	 to	 precipitate	 the	 product	 as	 an	 ammonium	 salt.	 The	precipitate	was	collected	by	centrifugation	at	4400	rpm	at	room	temperature	for	15	min,	and	the	resulting	pellet	was	washed	twice	with	30	mL	of	acetone	and	dried	under	high	vacuum.	Products	3.7a−d	were	obtained	as	ammonium	salts.	
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1-(2′-Deoxy-α-L-threofuranosyl)thymine-3′-monophosphate	(4.7a).	General	procedure	B	was	used	with	 the	 following:	0.39	g	(0.8	mmol)	of	4.6a,	8	mL	of	MeOH,	and	130	mg	of	10%	Pd/C;	1H	NMR	(400	MHz,	CD3OD)	δ	7.57	(s,	1H),	6.12	(dd,	1H,	J	=	9.2,	6.0	Hz),	4.93	(s,	1H),	4.37	(d,	1H,	J	=	10.4	Hz),	3.96	(d,	1H,	J	=	8.4	Hz),	2.63	(m,	1H),	2.30	(d,	1H,	J	=	15.2	Hz),	1.88	(s,	3H);	13C	NMR	(125.8	MHz,	CD3OD)	δ	165.1,	151.0,	136.8,	109.5,	85.5,	75.5,	47.1,	39.1,	11.1;	 31P	NMR	δ	 :	−0.11;	HRMS	(ESI-TOF)	C9H13N2O7PNa	 [M	+	Na]+	315.0356;	found	315.0356.		
1-(2′-Deoxy-α-L-threofuranosyl)cytosine-3′-monophosphate	(4.7b).	General	procedure	B	was	used	with	the	following:	350	mg	(0.62	mmol)	of	4.6b,	10	mL	of	MeOH,	and	70	mg	of	10%	Pd/C;	yield	165	mg	(96.5%,	ε271:	13100);	1H	NMR	(400	MHz,	DMSO-d6)	δ	7.72	(d,	1H,	J	=	7.6	Hz),	5.91	(dd,	2H,	J	=	29.2,	7.6	Hz),	4.68	(s,	1H),	4.21	(d,	1H,	J	=	10.4	Hz),	3.87	(d,	1H,	J	=	10.4	Hz),	2.42	(m,	1H),	2.16	(d,	1H,	J	=	15.6	Hz);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	164.7,	154.4,	142.0,	93.7,	85.6,	75.3,	72.9,	40.4;	31P	NMR	(162	MHz,	DMSO-
d6)	δ	−0.51;	HRMS	(ESI)	C8H12N3O6PNa2	[M	−	H	+	2Na]+	322.0181;	found	322.0185.		
9-(2′-Deoxy-α-L-threofuranosyl)adenine-3′-monophosphate	(4.7c).	General	procedure	B	was	used	with	 the	 following:	1.3	g	 (2.2	mmol)	of	4.6c,	15	mL	of	MeOH,	and	200	mg	of	10%	Pd/C;	yield	650	mg	(97.8%,	ε259:	15200);	 1H	NMR	(400	MHz,	DMSO-d6)	δ	8.34	(s,	1H),	8.15	(s,	1H),	7.22	(s,	1H),	6.32	(d,	1H,	J	=	7.2	Hz),	4.91	(s,	1H),	4.17	(d,	1H,	J	=	9.6	Hz),	3.96	(dd,	1H,	J	=	9.2,	3.6	Hz),	2.75	(m,	1H),	2.52	(m,	1H);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	155.9,	152.6,	149.4,	139.4,	118.5,	82.5,	74.6	(d,	J	C,P	=	4.2	Hz),	73.2	(d,	J	C,P	=	
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3.7	Hz),	 38.8;	 31P	NMR	 (162	MHz,	DMSO-d6)	δ	−0.20;	HRMS	 (ESI)	C9H12N5O5PH	 [M	+	H]+	302.0654;	found	302.0668.		
9-(2′-Deoxy-α-L-threofuranosyl)guanine-3′-monophosphate	(4.7d).	In	the	first	step,	general	procedure	B	was	used	with	the	following:	0.73	g	(1.4	mmol,	1	equiv)	of	4.6a,	15	mL	of	MeOH,	and	180	mg	of	10%	Pd/C);	silica	gel	TLC	(CH2Cl2/MeOH	10:1)	Rf	=	0.35.	In	the	second	step,	the	conditions	of	general	procedure	B	and	5	mL	30%	NH4OH	in	37	°C	for	18	h	were	followed:	1H	NMR	(400	MHz,	D2O)	δ	8.17	(s,	1H),	6.31	(d,	1H,	J	=	9.6	Hz),	5.06	(s,	1H),	4.36	(d,	1H,	J	=	8.0	Hz),	4.19	(d,	1H,	J	=	8.4	Hz),	2.86	(s,	2H),	2.68	(d,	2H,	J	=	8.0	Hz),	2.27	(s,	3H);	13C	NMR	(125.8	MHz,	DMSO-d6)	δ	156.8,	153.6,	150.9,	136.1,	115.9,	81.8,	74.5,	72.1,	48.5,	40.0,	30.5;	31P	NMR	(162	MHz,	DMSO-d6)	δ	0.84;	HRMS	(ESI)	C9H11N5O6PNa2	[M	−	H	+	2Na]+	362.0242;	found	362.0250.	
General	Procedure	C	for	the	Preparation	of	4.8a−d.		To	 a	 solution	 containing	 1	 equiv	 of	 4.7a−d	 in	 anhydrous	 DMSO	 was	 added	 5	 equiv	 of	trimethylamine	 followed	 by	 2.5	 equiv	 of	 2-methylimidazole,	 2.5	 equiv	 of	triphenylphosphine,	and	2.5	equiv	of	2,	2′-dipyridyldisulfide	sequentially.	The	reaction	was	stirred	under	a	nitrogen	atmosphere	 for	6−8	h	at	 room	 temperature	with	monitoring	by	analytical	HPLC.	When	 the	HPLC	showed	 that	 the	reaction	was	 finished,	 the	product	was	precipitated	by	adding	dropwise	the	reaction	mixture	to	a	stirring	solution	containing	80	mL	of	acetone,	60	mL	of	diethyl	ether,	5	mL	of	triethylamine,	and	5	mL	of	saturated	NaClO4	in	acetone.	The	precipitate	was	collected	by	centrifugation	at	4400	rpm	for	15	min	at	room	temperature.	The	pellet	was	washed	twice	with	30	mL	of	washing	solution	(acetone/diethyl	
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ether	1:1)	and	dried	under	high	vacuum	to	afford	white	solid	products	4.8a−d	as	sodium	salts.		
1-(2′-Deoxy-α-L-threofuranosyl)thymine-3′-phosphor-2-methylimidazolide	(4.8a).	General	procedure	C	was	used	with	the	following:	100	mg	(0.36	mmol)	of	4.7a,	5	mL	of	anhydrous	 DMSO,	 250	 μL	 (1.8	 mmol)	 of	 trimethylamine,	 236	 mg	 (0.9	 mmol)	 of	triphenylphosphine,	and	198	mg	(0.9	mmol)	of	2,	2′-dipyridyldisulfide;	product	yield	115		mg	(97.4%,	ε267	=	9600);	31P	NMR	(162	MHz,	D2O)	δ	−7.81;	HRMS	(ESI-TOF)	C13H16N4O6P	[M	−	H]−	355.0787;	found	355.0800.		
1-(2′-Deoxy-α-L-threofuranosyl)cytosine-3′-phosphor-2-methylimidazolide	(4.8b).	General	procedure	C	was	used	with	the	following:	100	mg	(0.4	mmol)	of	4.7b,	2	mL	of	anhydrous	 DMSO,	 250	 μL	 (1.8	 mmol)	 of	 trimethylamine,	 236	 mg	 (0.9	 mmol)	 of	triphenylphosphine,	and	198	mg	(0.9	mmol)	of	2,	2′-dipyridyldisulfide;	product	yield	118	mg	(95.4%,	ε280:	13100),	HPLC	retention	time;	31P	NMR	(162	MHz,	D2O)	δ	−7.99;	HRMS	(ESI-TOF)	C12H15N5O5PNa2	[M	+	2Na]+	386.0606;	found	386.0617.		
9-(2′-Deoxy-α-L-threofuranosyl)adenine-3′-phosphor-2-methylimidazolide	(4.8c).	General	procedure	C	was	used	with	the	following:	40	mg	of	4.7c	(0.15	mmol),	1	mL	of	anhydrous	 DMSO,	 104	 μL	 (0.8	 mmol)	 of	 trimethylamine,	 79	 mg	 (0.3	 mmol)	 of	triphenylphosphine,	and	66	mg	(0.3	mmol)	of	2,	2′-dipyridyldisulfide;	product	yield	45	mg		(96.5%,	ε259:	15200),	HPLC	retention	time;	31P	NMR	(162	MHz,	D2O)	δ	−7.88;	HRMS	(ESI-TOF)	C13H15N7O4P	[M	−	H]−	364.0923;	found	364.0936.	
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9-(2′-Deoxy-α-L-threofuranosyl)guanine-3′-phosphor-2-methylimidazolide	(4.8d).	General	procedure	C	was	used	with	the	following:	50	mg	of	4.7d	(0.13	mmol),	1	mL	of	anhydrous	 DMSO,	 104	 μL	 (0.8	 mmol)	 of	 trimethylamine,	 79	 mg	 (0.3	 mmol)	 of	triphenylphosphine,	and	66	mg	(0.3	mmol)	of	2,	2′-dipyridyldisulfide;	product	yield	60	mg		(93.5%,	ε259:	13700);	31P	NMR	(162	MHz,	D2O)	δ	−8.15;	HRMS	(ESI-TOF)	C13H16N7O5PNa	[M	+	Na]+	404.0848;	found	404.0847.		
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5.2	Abstract	of	the	Chapter	Natural	 and	 chemically	modified	nucleoside	 triphosphates	 impact	nearly	 every	major	aspect	of	healthcare	research	from	DNA	sequencing	to	drug	discovery.	However,	a	scalable	synthetic	route	to	these	molecules	has	long	been	hindered	by	the	need	for	purification	by	high	performance	 liquid	 chromatography	 (HPLC).	We	describe	 a	 fundamentally	 different	
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approach	that	uses	a	novel	P(V)	pyrene	pyrophosphate	reagent	to	generate	derivatives	that	are	purified	by	silica	gel	chromatography	and	converted	to	the	desired	compounds	on	scales	vastly	 exceeding	 those	achievable	by	HPLC.	The	power	of	 this	 approach	 is	demonstrated	through	the	synthesis	of	a	broad	range	of	natural	and	unnatural	nucleoside	triphosphates	using	efficient,	inexpensive,	and	operationally	straightforward	protocols.		
5.3	Introduction	Polymerases	are	among	the	most	powerful	tools	in	the	molecular	biology	arsenal,	permitting	researchers	to	precisely	synthesize	the	DNA	sequences	of	genes,	gene	clusters,	and	entire	genomes	for	diverse	applications	ranging	from	basic	research	to	biotechnology	and	 medicine.	 1,2	 Polymerase-mediated	 DNA	 synthesis	 has	 reduced	 the	 cost	 of	 DNA	sequencing	 by	 allowing	 next-generation	 sequencing	 (NGS)	 platforms	 to	 read	 massive	numbers	of	amplicons	and	has	enabled	digital	archiving	by	compressing	 information	into	strands	of	DNA	sequences	that	can	be	read	by	NGS	analysis	and	decoded	by	bioinformatic	assembly.	3,4	Engineered	polymerases,	developed	by	directed	evolution,	have	also	grown	in	demand	by	enabling	the	synthesis	of	artificial	genetic	polymers	with	backbone	structures	that	are	distinct	from	those	found	in	nature.	5,6	Such	enzymes	are	now	used	to	support	the	evolution	of	affinity	reagents	(aptamers)	and	catalysts	with	molecular	compositions	that	are	better	equipped	to	function	in	harsh	biological	environments.	7-10	Today,	no	single	strategy	has	been	developed	that	can	be	applied	universally	to	the	synthesis	 of	 all	 nucleoside	 triphosphates.	 Natural	 DNA	 triphosphates	 (dNTPs)	 used	 to	support	traditional	DNA	synthesis	applications	are	manufactured	using	enzymatic	methods,	while	 modified	 nucleoside	 triphosphates	 developed	 for	 biotechnology	 and	 medicinal	
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Figure	5.1.	HPLC	analysis	of	a-L-threofuranosyl	adenosine	triphosphate	using	the	traditional	Yoshikawa	or	Ludwig-Eckstein	methods.	Red	arrow	indicates	the	location	of	the	desired	peak	in	the	crude	reaction	mixture.		(Figure	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019.	141,	34,	13286-13289)			 Efforts	to	synthesize	nucleoside	triphosphates	independent	of	HPLC	purification	first	appeared	in	2014	with	a	phosphorylation	strategy	that	involves	iterative	cycles	of	coupling,	oxidation,	and	deprotection.16-18	This	is	a	P(III)-based	reagent	method	that	relies	on	derivatized	phosphoramidite	reagents	to	facilitate	P-O	bond	formation.	Free	nucleosides	are	converted	to	nucleoside	triphosphates	through	the	production	of	P(III)-P(V)	anhydride	intermediates	that	are	oxidized	and	deprotected	during	each	cycle	of	P(V)	phosphate	generation.	16	The	iterative	strategy	benefits	from	high	yields,	rapid	coupling	rates,	and	convenient	 (non-dry)	 reaction	 conditions	 but	 is	 marked	 by	 several	 disadvantages	 that	include:	(1)	the	need	for	quantitative	functional	group	transformations,	which	are	necessary	to	avoid	the	accumulation	of	unwanted	side	products;	(2)	prolonged	deprotection	conditions	due	to	slow	removal	of	the	second	P-O	protecting	group	on	the	phosphorylating	reagent;	(3)	incompatibility	with	certain	chemical	reagents	and	nucleoside	protecting	groups;	and	(4)	a	lengthy	 pathway	 that	 involves	 9	 functional	 group	 transformations	 to	 convert	 each	nucleoside	to	its	corresponding	triphosphate.16-18	In	attempt	to	address	these	concerns,	we	conceived	a	fundamentally	different	approach	for	the	synthesis	of	natural	and	modified	nucleoside	triphosphates	that	required	invention	of	 a	 novel	 P(V)-based	 organic	 pyrophosphate	 reagent	 to	 mediate	 P-O	 bond	 formation	between	 the	 a-	 and	b-phosphate	positions.	Our	 vision	was	 to	 establish	 an	Hoard-Ott-like	
124		




Figure	5.2.	Strategy	and	methodology	development.	Vision	for	the	scalable	synthesis	of	natural	and	modified	nucleoside	triphosphates	using	a	new	class	of	organopyrophosphate	reagents.	R,	the	aromatic	substitution	attached	to	a	cleavable	sulfonylethyl	linker.	LG,	leavinggroup	moiety.	B,	nucleobase	moieties:	adenine	(A),	guanine	(G),	cytosine	(C),	thymine	(T).			 (Figure	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019.	141,	34,	13286-13289)		 The	 goals	 of	 our	 study	 were	 ultimately	 met	 through	 a	 systematic	 exploration	 and	subsequent	 optimization	 of	 reaction	 conditions	 which	 revealed	 that	 pyrene,	 2-methylimidazole,	and	zinc	chloride	provided	the	optimal	hydrophobic	moiety,	leaving	group,	
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Figure	 5.3.	 ORTEP	 representation	 of	 2-(pyrenesulfonylethyl)	 pyrophosphate	 (7)	 with	thermal	 ellipsoids	 at	 the	 50%	 probability	 level.	 Crystals	 were	 prepared	 using	 the	 vapor	diffusion	method.	The	compound	was	dissolved	in	a	minimal	amount	of	methanol	in	a	2	mL	open	vial,	which	was	placed	in	a	20	mL	sealed	vial	containing	4	mL	of	anhydrous	toluene.	The	 crystal	 grew	 over	 a	 1-month	 period	 under	 vapor	 equilibrium	 conditions	 at	 room	temperature.		 (Figure	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)			
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Figure	5.4.	Synthesis	and	purity	comparison	of	thymidine	triphosphate.	(a)	Application	of	the	organopyrophosphate	reagent	to	the	synthesis	of	natural	thymidine-5’-triphosphate.	(b)	HPLC	 traces	 provided	 for	 the	 activated	monophosphate,	 fully	 protected	 triphosphate	
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intermediate	after	silica	gel	purification,	and	thymidine	triphosphate	after	precipitation	as	the	sodium	salt.	(c)	Comparison	of	chemically	synthesized	thymidine	3’-triphosphate	(dTTP)	with	a	commercial	standard.	thymidine-5’-triphosphate	(the	mirror	image	form	of	natural	D-dTTP).		







Figure	5.5.	Synthesis	of	thymidine	triphosphate	analogs.	The	organopyrophosphate	reagent	was	applied	to	the	synthesis	of	thymidine	3’-triphosphate,	a-L-threofuranosyl	thymidine	3’-	triphosphate,	and	L-thymidine	5’-triphosphate.	HPLC	traces	provided	after	precipitation	as	the	sodium	salt.		 (Figure	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)		 Next,	we	prepared	a	complete	set	of	DNA	nucleoside	triphosphates	(dNTPs)	using	the	pyrene	pyrophosphate	method.	Each	activated	nucleoside	monophosphate	was	converted	to	the	 desired	 nucleoside	 triphosphate	 following	 the	 standard	 procedure	 of	 pyrene	pyrophosphate	 coupling,	 purification	 by	 silica	 gel	 chromatography,	 deprotection	 with	concentrated	 ammonium	 hydroxide,	 and	 precipitation	 as	 the	 sodium	 salt	 (Fig.	 5.6a).	Concurrently,	we	also	synthesized	all	four	TNA	nucleoside	triphosphates	(tNTPs),	which	are	
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the	 substrates	 for	 engineered	 TNA	 polymerases	 developed	 by	 directed	 evolution	 (Fig.	
5.6b)21.	 In	 all	 cases,	 analytical	 HPLC	 chromatograms	 reveal	 high	 conversion	 (>95%)	 of	activated	 nucleoside	 triphosphate	 into	 the	 fully	 protected	 nucleoside	 triphosphate.	Following	 deprotection	 and	 precipitation,	 the	 desired	 DNA	 and	 TNA	 nucleoside	triphosphates	 were	 produced	 in	 highly	 pure	 form	 on	 scales	 (>500	 milligrams)	 and	timeframes	(2-3	days)	vastly	exceeding	those	of	traditional	protocols.	Since	 nucleoside	 triphosphates	 would	 ultimately	 be	 used	 as	 substrates	 for	oligonucleotide	synthesis,	we	chose	to	investigate	the	use	of	these	reagents	in	a	conventional	DNA	 synthesis	 assay.	 One	 critical	 question	 that	 our	 study	 aimed	 to	 address	 is	 whether	chemically	 synthesized	 DNA	 triphosphates	 function	 with	 same	 level	 of	 efficiency	 as	enzymatically	 produced	 dNTPs	 obtained	 from	 commercial	 venders.	 To	 address	 this	question,	the	polymerase	chain	reaction	(PCR)	was	used	to	amplify	an	arbitrary	DNA	sample	in	reaction	mixtures	that	contained	either	chemically	synthesized	or	commercial	dNTPs.	We	chose	to	amplify	a	200	base	pair	segment	that	defines	the	finger	subdomain	of	an	archaeal	DNA	polymerase	isolated	from	the	thermophilic	species	Thermococcus	kodakarensis	(Kod).	





Figure	 5.6.	 	 Polymerase	 activity	 assay	 of	 chemically	 synthesized	 DNA	 and	 TNA	
nucleoside	 triphosphates.	 All	 four	 DNA	 and	 TNA	 nucleoside	 triphosphates	 were	constructed	using	 the	organic	 pyrophosphate	method.	 (a)	 Chemically	 synthesized	dNTPs	were	 evaluated	 against	 commercial	 reagents	 in	 a	 standard	 PCR	 reaction.	 (b)	 Chemically	synthesized	tNTPs	purified	by	silica	gel	chromatography	(SG)	were	evaluated	against	HPLC	purified	tNTPs	(HPLC)	 in	a	polymerase-mediated	primer-extension	reaction	using	Kod-RI	TNA	polymerase.	(Figure	was	used	with	permission	from	.		J.	Am.	Chem.	Soc.		2019,	141,	34,	13286-13289)	
	Next,	we	evaluated	the	set	of	chemically	synthesized	TNA	triphosphates	as	substrates	for	TNA	synthesis	using	an	engineered	TNA	polymerase.	25	In	this	assay,	a	DNA	primer-template	complex	was	extended	with	TNA	using	either	newly	synthesized	tNTPs	or	tNTPs	obtained	by	a	traditional	Hoard-Ott-like	approach	that	requires	HPLC	purification.	26	Analysis	of	the	resulting	 primer-extension	 reactions	 by	 denaturing	 polyacrylamide	 gel	 electrophoresis	
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General	Information	All	moisture	sensitive	reactions	were	carried	out	in	anhydrous	solvents	under	an	argon	or	nitrogen	atmosphere.	All	commercial	reagents,	solvents	and	anhydrous	solvents	were	used	without	further	purification.	Solvents	used	for	triphosphate	purification	by	silica	column	 chromatography	 were	 purchased	 as	 HPLC	 grade.	 Reaction	 progresses	 were	monitored	by	 thin	 layer	chromatography	using	glass-backed	analytical	SiliaPlate	with	UV	active	F254	indicator.	Flash	column	chromatography	was	performed	with	SiliaFlash.	P60	silica	gel	(40-63	um	particle	size).		
1H,	 13C,	 or	 31P	 Nuclear	 Magnetic	 Resonance	 (NMR)	 spectra	 were	 recorded	 at	 room	temperature	 either	 on	 a	 Bruker	DRX	 400	 or	 500	MHz	 spectrometer	 at	 the	University	 of	California,	Irvine	NMR	Facility.	The	1H	and	13C	NMR	chemical	shifts	(δ)	are	reported	in	parts	per	million	(ppm)	with	tetramethylsilane	or	deuterium	solvent	as	an	internal	reference.	The	31P	NMR	chemical	shifts	are	proton	decoupled	and	reported	in	parts	per	million	referenced	to	the	deuterium	solvent	calibrated	in	1H	NMR.	Peaks	multiplicity	are	designated	with	the	following	 abbreviations:	 s,	 singlet;	 d,	 doublet;	 dd,	 doublet	 of	 doublets;	 ddd,	 doublet	 of	doublet	of	doublets;	 t,	 triplet;	m,	multiplet;	br,	broad.	X-ray	crystal	data	was	collected	by	Bruker	 SMART	 APEX	 II	 diffractometer	 at	 University	 of	 California,	 Irvine	 X-ray	Crystallography	Facility.	
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HPLC	analysis	was	performed	on	a	reverse-phase	C18	150	Å~	4.6	mm2	column	with	5	μm	particle	size	(Agilent,	USA)	using	a	mobile	phase	of	100	mM	triethylammonium	acetate	buffer	(pH	7.0)/acetonitrile.	High	resolution	mass	spectrometry	(HRMS)	data	were	acquired	using	the	electrospray	ionization	time-of-flight	(ESI-TOF)	method	at	the	University	 of	 California,	 Irvine	 Mass	 Spectrometry	 Core	 Facility.	 The	 nucleoside	monophosphates,	phosphorimidazolides	and	triphosphates	were	dissolved	in	RNase-free	water	with	10	mM	Tris	pH	8.0	and	quantified	by	Nanodrop	2000	(Thermo	Scientific,	USA)	using	Beer’s	law.	(T,	ε267:	9600	M−1cm−1.	C,	ε280:	13100	M−1cm−1.	G,	ε253:	13700	M−1cm−1.	A,	ε259:	15200	M−1cm−1.)		
SYNTHESIS	OF	PYRENE	PYROPHOSPHATE	
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1-(2-(Pyrenesulfonyl)ethyl)-(β-dibenzyl)pyrophosphate	(5.6).	To	the	4.42	g	(11.3	mmol)	of	1-(2-(pyrenesulfonyl)ethyl)	monophosphate	(5.5)	in	39.3	mL	of	anhydrous	dichloromethane	was	added	5.33	mL	(15.8	mmol)	of	(BnO)2PN(i-Pr)2	at	room	temperature	under	a	nitrogen	atomosphore.	After	two	hours	stirring,	the	reaction	was	slowly	added	to	6.16	mL	(33.9	mmol)	of	tert-butyl	hydrogen	peroxide	(5.5	M	in	decane)	at	-40	 oC	 and	 stirred	 for	 an	 additional	 30	 minutes	 at	 room	 temperature.	 The	 reaction	 was	evaporated	under	diminished	pressure	and	the	crude	product	was	purified	by	silica	column	chromatography	with	the	eluents	(MeCN	then	MeOH/CH2Cl2	from	1%	to	3%	containing	 1%	 triethylamine)	 to	 afford	 the	 solid	 product	5.6;	 	 yield:	 6.5	 g	 (76.6%);	 TLC	(2:100	MeOH-CH2Cl2	with	1%	triethylamine)	Rf	=	0.26;	1H	NMR	(400	MHz,	CD3OD)	δ	8.90	(d,	1H,	J	=	9.6	Hz),	8.56	(d,	1H,	J	=	8.0	Hz),	8.15-8.11	(m,	3H),	8.06-8.00	(m,	2H),	7.94	(t,	1H,	J	=	8.0	Hz),	7.87	(d,	1H,	J	=	8.8	Hz),	7.19	(m,	10H),	4.94	(d,	4H,	J	=	7.6	Hz),	4.32	(dd,	2H,	J	=	15.2,	6.8	Hz),	3.75	(t,	2H,	 J	=	6.8	Hz);	13C	NMR	(125.8	MHz,	CDCl3)	δ	136.0,	135.9,	135.6,	130.9,	130.7,	130.7,	130.6,	130.0,	129.1,	128.5,	128.3,	127.8,	127.7,	127.3,	127.2,	127.1,	127.0,	125.1,	124.3,	124.0,	122.6,	69.3	(d,	J	C,P	=	5.5	Hz),	59.7	(d,	J	C,P	=	5.5	Hz),	57.0	(d,	J	C,P	=	6.9	Hz);	31P	NMR	(162	MHz,	CDCl3)	δ	-11.2	(d,	J	=	18.5	Hz),	-	11.6	(d,	J	=	18.5	Hz);	HRMS	(ESI-TOF)	calcd.	for	C32H27O9P2SNa2	[M-H+2Na]+	695.0646;	found	695.0660.		
1-2-(Pyrenesulfonyl)ethyl)pyrophosphate	(5.7).	To	a	solution	containing	6.5	g	of	1-(2-(pyrenesulfonyl)ethyl)-(β-dibenzyl)pyrophosphate	
(4.6)	 in	30	mL	of	MeOH	was	purged	with	nitrogen	gas.	The	solution	was	added	to	0.1-0.2	mass	equivalent	of	10%	Pd/C	and	purged	with	nitrogen	gas	followed	by	adding	hydrogen	gas.	 The	 mixture	 was	 stirred	 at	 room	 temperature	 for	 3	 h	 with	 monitoring	 by	 TLC	
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(MeOH/CH2Cl2,	 1:10	with	 1%	Et3N).	 The	 resulting	 suspension	was	 filtered	 over	 a	 pad	 of	celite,	washed	with	100	mL	of	MeOH	three	times,	evaporated,	and	coevaporated	with	dry	C2H4Cl2	under	reduced	pressure	to	afford	the	product	as	a	yellowish	solid	5.7;	yield:	4.27	g	(90.9%);	TLC	(MeOH/CH2Cl2,	1:10	with	1%	triethylamine)	Rf	=	0;	1H	NMR	(400	MHz,	CD3OD)	δ	8.93	(d,	1H,	J	=	9.2	Hz),	8.61	(d,	1H,	J	=	8.0	Hz),	8.29-8.22	(m,	4H),	8.13	(d,	1H,	J	=	8.8	Hz),	8.05-8.00	(m,	2H),	4.35	(m,	2H),	3.91	(t,	2H,	J	=	10.4	Hz);	13C	NMR	(125.8	MHz,	D2O)	δ	135.0,	130.7,	130.1,	129.7,	129.2,	129.0,	128.3,	127.3,	127.1,	127.0,	126.6,	126.3,	124.4,	123.6,	122.4,	121.8,	60.6,	57.3	(d,	J	C,P	=	6.0	Hz);	31P	NMR	(162	MHz,	D2O)	δ	-10.0	(d,	J	=	16.8	Hz),	-11.5	(d,	
J	 =	 16.8	 Hz);	 HRMS	 (ESI-TOF)	 calcd.	 For	 C18H14O9P2SNa3	 [M-2H+3Na]+	 536.9527;	 found	536.9521.		
SYNTHESIS	OF	NUCLEOSIDE	TRIPHOSPHATES	
General	procedure	A:	synthesis	of	protected	nucleoside	monophosphates.	To	a	mixture	containing	suitably	protected	free	nucleoside	(compounds:	5.8a-d,	5.14,	5.20a-d,	and	5.26)	and	1.8	equivalents	of	tetrazole	in	an	anhydrous	solvent	(MeCN/CH2Cl2,	1:1)	was	added	to	1.3	equivalents	of	(BnO)2PN(i-Pr)2	under	a	nitrogen	atmosphere.	The	mixture	was	stirred	at	room	 temperature	 for	 1-3	 hours	 and	 the	 reaction	 was	monitored	 by	 TLC.	 At	 which	 the	starting	material	was	consumed,	the	reaction	was	slowly	added	excess	H2O2	(33%	in	H2O)	at	-40	oC	and	the	resulting	mixture	was	stirred	at	room	temperature	for	1	hour.	The	solution	was	then	diluted	with	15-20	times	volume	of	CH2Cl2	and	the	organic	layer	was	sequentially	washed	with	saturated	NaHCO3(aq),	brine,	and	water.	The	organic	extracts	were	combined,	dried	 with	 MgSO4,	 and	 evaporated	 under	 diminished	 pressure.	 The	 crude	 residue	 was	
141		
purified	 by	 silica	 gel	 chromatography	 and	 the	 fractions	 containing	 the	 product	 were	collected	and	evaporated	to	afford	the	product	5.9a-d,	5.15,	5.21a-d,	or	5.27.	
General	 procedure	 B:	 synthesis	 of	 nucleoside	 monophosphates.	 To	 a	 solution	containing	the	protected	nucleoside	monophosphate	(compounds	5.9a-d,	5.15,	5.21a-d,	and	5.27)	 in	 MeOH	 was	 purged	 with	 nitrogen	 gas.	 The	 solution	 was	 added	 0.1-0.2	 mass	equivalent	of	10%	Pd/C,	and	re-purged	with	nitrogen	gas	followed	by	adding	hydrogen	gas.	The	 mixture	 was	 stirred	 at	 room	 temperature	 for	 3-5	 hours	 with	 monitoring	 by	 TLC	(MeOH/CH2Cl2,	1:10	with	1%	triethylamine).	Then	the	solution	was	purged	with	nitrogen,	filtered	over	a	pad	of	celite,	and	washed	with	MeOH	or	MeOH	containing	2%	triethylamine.	The	filtrate	was	collected,	evaporated	and	coevaporated	with	dry	1,	2-dichloroethane	under	reduced	pressure	to	afford	the	product	5.10a-d,	5.16,	5.22a-d,	or	5.28.	
General	procedure	C	:	synthesis	of	activated	nucleoside	monophosphates.	To	a	solution	containing	 the	 nucleoside	monophosphate	 (compounds	 5.a-d,	 5.16,	 5.22a-d	 and	 5.28)	 in	anhydrous	DMF	under	a	nitrogen	atmosphere	was	slowly	added	5	equivalents	of	anhydrous	triethylamine	at	0	oC.	After	5	minutes	with	stirring,	2	equivalents	of	2-	methylimidazole	was	added	followed	by	2	equivalents	of	triphenylphosphine.	After	10	minutes	of	stirring	at	room	temperature,	2	equivalents	of	2,	2’-dipyridyl	disulfide	was	added	and	stirring	was	continued	for	an	additional	3	hours	at	room	temperature	with	monitoring	by	analytical	HPLC	(mobile	phase:	MeCN/0.1	M	TEAA	buffer,	from	0%	to	50%	over	40	minutes).	After	consumption	of	the	starting	material,	 the	product	was	precipitated	by	adding	 the	reaction	dropwise	with	stirring	to	300	mL	of	diethyl	ether.	The	precipitate	was	collected	by	centrifuging	at	4400	rpm	for	15	minutes	at	 room	 temperature.	The	 supernatant	was	discarded,	 and	 the	pellet	was	resuspended	with	minimal	 amount	 of	 CH2Cl2	 or	 anhydrous	DMF	 (DMF	 is	 used	when	 the	
142		
nucleoside	monophosphate	is	not	soluble	in	CH2Cl2).	The	solution	was	added	dropwise	to	a	premade	solution	of	ether/ethyl	acetate/triethylamine	(5:10:1)	containing	8	equivalents	of	sodium	perchlorate	for	a	second	precipitation.	The	suspended	solid	was	centrifuged	at	4400	rpm	for	15	minutes	at	room	temperature,	the	supernatant	was	discarded,	and	the	pellet	was	washed	twice	with	40	mL	of	mixed	solvent	(ether/ethyl	acetate,	1:2),	and	dried	under	high	vacuum	to	afford	the	product	5.11a-d,	5.17,	5.23a-d	or	5.29.	























































MeCN/CH2Cl2, r.t., 3 h
30 % H2O2, (3 eq)
1 h
H2, Pd/C














PPh3 (2.5 eq), ET3N (5 eq)


















































































































MeCN/CH2Cl2, r.t., 1 h
30 % H2O2, (3 eq)
1 h
H2, Pd/C













PPh3 (2.5 eq), ET3N (5 eq)
































































3’-O,	N4-Dibenzoyl-2’-deoxycytidine-5’-dibenzylmonophosphate	(5.9b).	General	 procedure	A	with	1.04	 g	 (2.4	mmol)	 of	 3’-O,	N4-dibenzoyl-2’-deoxythymidine	





3’-O,	N4-Dibenzoyl-2’-deoxycytidine-5’-phosphor-2-methylimidazolide	(5.11b).	General	procedure	C	with	1.05	g	(1.5	mmol)	of	5.10b,	7.3	mL	of	anhydrous	DMF,	1.02	mL	(7.3	mmol)	of	triethylamine,	252	mg	(3.0	mmol)	of	2-methylimidazole,	918	mg	(3.5	mmol)	of	triphenylphosphine,	804	mg	(3.7	mmol)	of	dipyridyl	disulfide	for	2	hours	reaction	at	room	temperature.	First	precipitation	was	achieved	with	250	mL	of	diethyl	ether.	The	product	was	resuspended	with	10	mL	of	DMF	and	dropwise	added	to	the	solution	containing	1.79	g	of	sodium	 perchlorate,	 15	 mL	 of	 triethylamine	 in	 300	 mL	 of	 mixing	 solution	 (ethyl	acetate/ether	 1.5:1)	 for	 second	 precipitation.	 The	 product	was	 afforded	 as	 a	white	 solid	
5.11b;	yield:	0.82	g	(93.4%);	31P	NMR	(162	MHz,	D2O)	δ	-6.63;	HRMS	(ESI-TOF)	calcd.	for	C27H25N5O8PNa2	[M-H+2Na]+	624.1236;	found	624.1256.		
3’-O,N4-Dibenzoyl-2’-deoxycytidine-5’-(γ-(2-(pyrenesulfonyl)ethyl))triphosphate	
(5.12b).	General	 procedure	 D	 with	 0.82	 g	 (1.4	 mmol)	 of	 5.11b,	 0.77	 g	 (1.6	 mmol)	 of	 1-(2-	(pyrenesulfonyl)ethyl)	pyrophosphate	(5.7)	and	13.6	mL	(13.6	mmol)	of	ZnCl2	solution	(1.0	M	in	anhydrous	DMF)	for	3	hours	with	stirring.	Then	crude	was	precipitated	by	dropwise	adding	 the	 solution	 to	 the	 300	mL	 of	 ethyl	 acetate	 with	 stirring	 for	 precipitation.	 After	centrifugation,	the	pellet	was	resuspended	by	20%	H2O/MeCN	containing	2%	Hunig’s	base	
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and	 filtered	 by	 pyrex	 glass	 funnel.	 The	 filtrate	 was	 evaporated	 and	 crude	 product	 was	purified	by	silica	column	chromatography	with	eluents	7%	H2O/isopropanol	containing	1%	diisopropylethylamine	(DIPEA)	and	then	H2O	in	(isopropanol/MeCN	1:1)	from	5%	to	8	%	containing	1%	diisopropylethylamine	(DIPEA)	to	afford	the	white	solid	5.12b;	yield:	1.07	g	(58.1	%);	 TLC	 (H2O/acetone	 1:10	 containing	 2%	DIPEA):	 Rf	 =	 0.32;	 1H	NMR	 (500	MHz,	D2O/DMSO-d6	1:1)	δ	11.15	(s,	1H),	8.91	(s,	1H),	8.60-7.95	(m,	7H),	7.62-	7.33	(m,	4H),	6.25	(s,	1H),	5.47	(s,	1H),	4.33-3.90	(m,	4H),	2.34	(s,	1H);	31P	NMR	(162	MHz,	D2O/DMSO-d6	1:1)	δ	-12.13	(d,	1P,	J	=	17.2	Hz),	-12.38	(d,	1P,	J	=	14.9	Hz),	-22.59	(brs,	1P);	HRMS	(ESI-TOF)	calcd.	for	C41H34N3O17P3SNa3	[M-2H+3Na]+	1034.0515;	found	1034.0485.		





































MeCN/CH2Cl2, r.t., 1 h
30 % H2O2, (3 eq)
1 h
H2, Pd/C











PPh3 (2.5 eq), ET3N (5 eq)





















































































solid	was	collected	by	centrifugation	at	4400	rpm	for	10	minutes	at	room	temperature.	The	crude	product	was	resuspended	with	minimal	volume	of	CH2Cl2	and	dropwise	added	to	300	mL	of	ether	containing	1.4	g	of	LiClO4.	The	precipitate	was	collected	by	centrifugation	at	4400	rpm	 for	 10	 minutes	 at	 room	 temperature	 to	 afford	 the	 white	 solid	 5.11c;	 yield:	 1.08	 g	(97.5%);	 31P	 NMR	 (162	 MHz,	 D2O)	 δ	 -7.59;	 HRMS	 (ESI-TOF)	 calcd.	 for	 C35H30N7O8PNa	[M+Na]+	730.1791;	found	730.1799.		
3’-O,	N6,	N6-Tribenzoyl-2’-deoxyadenosine	-5’-γ-(2-(pyrenesulfonyl)ethyl]-	

































MeCN/CH2Cl2, r.t., 1 h
30 % H2O2, (3 eq)
1 h
H2, Pd/C











PPh3 (2.5 eq), ET3N (5 eq)

































































































General	 procedure	 D	 with	 0.5	 g	 (0.81	 mmol)	 of	 5.11d,	 0.495	 g	 (1.0	 mmol)	 of	 1-(2-	(pyrenesulfonyl)ethyl)-pyrophosphate	(5.7)	and	5.38	mL	(8.0	mmol)	of	ZnCl2	solution	(1.5	M	in	anhydrous	DMF)	for	3	h	with	stirring.	After	the	reaction,	the	solution	was	precipitated	by	300	mL	of	ether.	Silica	column	chromatography	with	eluents	[(H2O	in	isopropanol/MeCN)	1:1	from	3%	to	8	%	containing	1%	diisopropylethylamine	(DIPEA)]	to	afford	the	white	solid	
5.12d;	yield:	1.07	g	(58.1	%);	TLC	(H2O/acetonitrile	1:10	containing	2%	DIPEA)	Rf	=	0.34;	


































MeCN/CH2Cl2, r.t., 3 h
30 % H2O2, (3 eq)
1 h
H2, Pd/C










PPh3 (2.5 eq), ET3N (5 eq)














































































5’-Benzoyl-2’-deoxythymidine-3’-phosphor-2-methylimidazolide	(5.17).	General	procedure	C	with	0.86	g	(2.0	mmol)	of	5.16,	10	mL	of	anhydrous	DMF,	1.39	mL	(10.0	mmol)	of	triethylamine,	328	mg	(4.1	mmol)	of	2-methylimidazole,	1.05	g	(4.0	mmol)	of	 triphenylphosphine,	 903	 g	 (4.0	 mmol)	 of	 dipyridyl	 disulfide.	 First	 precipitation	 was	
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achieved	in	250	mL	of	diethyl	ether.	The	product	was	resuspended	with	10	mL	of	DMF	and	dropwise	 added	 to	 the	 solution	 containing	 2.0	 g	 of	 sodium	 perchlorate,	 20	 mL	 of	triethylamine	 in	 400	mL	 of	 ethyl	 acetate	 for	 the	 second	 precipitation.	 The	 product	 was	afforded	as	a	white	solid	5.17;	yield:	0.89	g	(86.9%);	31P	NMR	(162	MHz,	D2O)	δ	-7.57;	HRMS	(ESI-TOF)	calcd.	for	C21H23N4O8PNa	[M+Na]+	513.1151;	found	513.1158.		
	


























MeCN/CH2Cl2, r.t., 3 h
30 % H2O2, (3 eq)
1 h
H2, Pd/C
MeOH, r.t., 3 h
2-methylimidazole (2.5 eq)
PPh3 (2.5 eq), ET3N (5 eq)

























































































1-(2’-O-benzoyl-α-L-threofuranosyl)thymidine-3’-dibenzylmonophosphate	(5.21a).	General	 procedure	 A	 with	 1g	 (3.0	 mmol)	 of	 1-(2’-O-benzoyl-α-L-threofuranosyl)	thymine,4	379.7	mg	(5.4	mmol)	of	tetrazole,	24	mL	of	anhydrous	solution	(MeCN/CH2Cl2,	1:1),	1.24	mL	(3.9	mmol)	of	dibenzyl-N,	N-diisopropylphosphoramidite	for	3	hours	stirring	at	 room	 temperature	 and	 6	mL	 of	 H2O2	 for	 1	 hour	 oxidation	 reaction.	 Silica	 gel	 column	chromatography	 with	 eluents	 (MeOH/CH2Cl2,	 from	 0	 to	 2%).	 The	 product	 5.21a	 was	acquired	 as	 a	white	 solid;	 yield:	 1.25	 g	 (70.1	%).	 This	 is	 a	 known	 compound	 previously	reported	in	the	literature.5	




triphenylphosphine,	0.88	g	(4	mmol)	of	dipyridyl	disulfide.	First	precipitation	was	achieved	with	 250	mL	 of	 diethyl	 ether.	 The	 product	 was	 resuspended	with	 15	mL	 of	 CH2Cl2	 and	dropwise	 added	 to	 the	 solution	 containing	 2.01	 g	 of	 sodium	 perchlorate,	 10	 mL	 of	triethylamine	in	300	mL	of	ethyl	acetate	for	the	second	precipitation.	The	product	5.23a	was	afforded	as	a	white	solid;	yield:	0.98	g	(98.3%);	31P	NMR	(162	MHz,	D2O)	δ	-8.17;	HRMS	(ESI-TOF)	calcd.	for	C20H21N4O8PNa	[M+Na]+	499.0995;	found	499.0992.			
1-(2’-O-benzoyl-α-L-threofuranosyl)thymidine-3’-(γ-(2-(pyrenesulfonyl)ethyl))	
























MeCN/CH2Cl2, r.t., 3 h
30 % H2O2, (3 eq)
1 h
H2, Pd/C
MeOH, r.t., 3 h
2-methylimidazole (2.5 eq)
PPh3 (2.5 eq), ET3N (5 eq)


























































































(5.21b)	Modified	general	procedure	A5	with	1g	(2.4	mmol)	of	N4-benzoyl-1-(2’-O-benzoyl-α-L-threofuranosyl)	cytosine	(5.20b),4	300	mg	(4.3	mmol)	of	tetrazole,	15.8	mL	of	anhydrous	solution	 (MeCN/CH2Cl2,	 1:1),	 0.98	 mL	 (3.1	 mmol)	 of	 dibenzyl-N,	 N-diisopropylphosphoramidite	for	1	hour	reaction	at	room	temperature	and	5	mL	of	H2O2	for	1	hour	oxidation	 reaction.	After	 the	 reaction,	 the	product	5.21b	was	afforded	as	 a	white	solid;	yield:	1.29	g	(79.3	%).	Additional	compound	characterization.5	
	
N4-Benzoyl-1-(2’-O-benzoyl-α-L-threofuranosyl)cytidine-3’-monophosphate	(5.22b).	General	procedure	B	with	1.29	g	(1.9	mmol)	of	5.21b,	50	mL	of	MeOH,	and	250	mg	of	10%	Pd/C	for	5	hours	stirring.	The	suspension	was	filtered	over	a	pad	of	celite,	washed	with	100	mL	of	MeOH	containing	2%	triethylamine	four	times.	The	product	5.22b	was	afforded	as	a	white	foam	of	a	triethylammonium	salt;	yield	1.23	g	(92.8%);1H	NMR	(400	MHz,	CDCl3)	δ	8.26	(d,	1H,	J	=	7.6	Hz),	7.99	(d,	2H,	J	=	7.2	Hz),	7.90	(d,	2H,	J	=	7.6	Hz),	7.57-7.53	(m,	2H),	7.47-7.39	(m,	5H),	6.18	(s,	1H),	5.66	(s,	1H),	4.91-4.85	(m,	2H),	4.28	(dd,	1H,	J	=	10.4,	3.2	Hz);	




General	procedure	C	with	1.02	g	(1.8	mmol)	of	5.22b,	4.3	mL	of	anhydrous	DMF,	0.87	mL	(6.4	mmol)	of	triethylamine,	287	mg	(3.5	mmol)	of	2-methylimidazole,	0.94	g	(3.6	mmol)	of	triphenylphosphine,	0.79	g	 (3.6	mmol)	of	dipyridyl	disulfide	 for	2	hours	 stirring	at	 room	temperature.	First	precipitation	was	achieved	with	200	mL	of	diethyl	ether.	The	product	was	resuspended	with	15	mL	of	CH2Cl2	and	dropwise	added	to	the	solution	containing	2.04	g	of	sodium	 perchlorate,	 10	 mL	 of	 triethylamine	 in	 300	 mL	 of	 ethyl	 acetate	 for	 the	 second	precipitation.	The	product	5.23b	was	afforded	as	a	white	solid;	yield:	0.94	g	(91.5%);	31P	NMR	(162	MHz,	D2O)	δ	-7.56;	HRMS	(ESI-TOF)	calcd.	for	C26H24N5O8PNa	[M+Na]+	588.1260;	found	588.1246.	
N4-Benzoyl-1-(2’-O-benzoyl-α-L-threofuranosyl)cytidine-3’-(γ-(2-





























MeCN/CH2Cl2, r.t., 3 h
30 % H2O2, (3 eq)
1 h
H2, Pd/C
MeOH, r.t., 3 h
2-methylimidazole (2.5 eq)
PPh3 (2.5 eq), ET3N (5 eq)












































































































































MeCN/CH2Cl2, r.t., 3 h
30 % H2O2, (3 eq)
1 h
H2, Pd/C
MeOH, r.t., 3 h
2-methylimidazole (2.5 eq)
PPh3 (2.5 eq), ET3N (5 eq)














































































































d6):	δ	173.5,	164.5,	154.8,	148.4,	148.1,	137.7,	134.1,	129.6,	128.9,	128.3,	119.9,	86.9,	80.6,	76.5,	72.8,	48.6,	23.8;	 31P	NMR	(162	MHz,	DMSO-d6):	δ	 	 -0.89;	HRMS	(ESI-TOF)	calcd.	 for	C18H18N5O9PNa	[M	+	Na]+	502.0740;	found	502.0727.		
N2-Acetyl-9-(2’-O-benzoyl-α-L-threofuranosyl)guanosine-3’-monophosphor-2-	
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methylimidazolide	(5.23d)	General	procedure	C	with	0.94	g	(1.9	mmol)	of	5.22d,	12	mL	of	anhydrous	DMF,	1.3	mL	(9.9	mmol)	of	triethylamine,	355	mg	(4.9	mmol)	of	2-methylimidazole,	1.29	g	(4.9	mmol)	of	triphenylphosphine,	 1.086	 g	 (4.9	 mmol)	 of	 dipyridyl	 disulfide.	 First	 precipitation	 was	achieved	with	150	mL	of	diethyl	ether.	The	product	was	resuspended	with	5	mL	of	CH2Cl2	and	 dropwise	 added	 to	 the	 solution	 containing	 1.5	 g	 of	 sodium	 perchlorate,	 6	 mL	 of	trimethylamine	in	150	mL	of	ethyl	acetate	for	the	second	precipitation.	The	product	afford	as	a	white	solid	5.23d;	yield:	0.88	g	(82.1	%);	31P	NMR	(162	MHz,	DMSO-d6):	δ		-9.77;	HRMS	(ESI-TOF)	calcd.	for	C22H22N7O8PNa	[M	+	Na]+	566.1165;	found	566.1163.		
N2-Acetyl-9-(2’-O-benzoyl-α-L-threofuranosyl)guanosine-3’-(γ-(2-




















MeCN/CH2Cl2, r.t., 3 h
30 % H2O2, (3 eq)
1 h
H2, Pd/C
MeOH, r.t., 3 h
2-methylimidazole (2.5 eq)
PPh3 (2.5 eq), ET3N (5 eq)
















































































































3’-Benzoyl-2’-deoxy-L-thymidine-5’-phosphor-2-methylimidazolide	(5.29)	General	procedure	C	with	180	mg	(0.42	mmol)	of	5.28,	8	mL	of	anhydrous	DMF,	300	μL	(2.1	mmol)	of	triethylamine,	86	mg	(1.0	mmol)	of	2-methylimidazole,	275	mg	(1.0	mmol)	of	triphenylphosphine,	242	mg	(1.0	mmol)	of	dipyridyl	disulfide	for	2	hours	reaction	at	room	temperature.	First	precipitation	was	achieved	with	50	mL	of	diethyl	ether.	The	product	was	resuspended	with	10	mL	of	DMF	and	dropwise	added	to	the	solution	containing	700	mg	of	sodium	 perchlorate,	 15	 mL	 of	 triethylamine	 in	 100	 mL	 of	 ethyl	 acetate	 for	 the	 second	precipitation.	The	product	was	afforded	as	a	white	solid	5.29;	yield:	145	mg	(96.9%);	31P	NMR	(162	MHz,	CD3OD)	δ	-7.85;	HRMS	(ESI-TOF)	C21H23N4O8PNa	[M+Na]+	513.1151;	found	513.1146		
3’-Benzoyl-2’-deoxy-L-thymidine-5’-(γ-(2-(pyrenesulfonyl)ethyl))triphosphate	





Analytical	Reverse-Phase	HPLC	Analysis.	2	μL	of	reaction	crude	(5.10-5.11a-d,	and	5.16-5.17,	and	5.22-5.23a-d,	and	5.28-5.29)	in	DMF	or	1	μL	of	purified	pyrene	substituted	nucleoside	triphosphates	(5.12a-d,	and	5.18,	and	5.24a-d,	and	5.30)	in	methanol	or	3	μL	of	nucleoside	triphosphates	(5.13a-d,	and	5.19,	and	5.25a-d,	and	5.31)	in	H2O	was	added	to	50	μL	of	0.1	M	triethylammonium	acetate	(TEAA)	buffer	pH	7.0.	The	solution	was	centrifuged	by	4000	rpm	for	2	minutes	at	room	temperature	and	30	μL	of	supernatant	was	injected	for	HPLC	analysis.	Reaction	progress	of	the	synthesis	of	 nucleoside	 monophosphates	 (5.10a-d,	 and	 5.16,	 and	 5.22a-d,	 and	 5.28),	 nucleoside	phosphor-	 2-methylimidazolides	 (5.11a-d,	 and	 5.17,	 and	 5.23a-d,	 and	 5.29),	 pyrene	
177		
substituted	 nucleoside	 triphosphates	 (5.12a-d,	 and	 5.18,	 and	 5.24a-d,	 and	 5.30)	 and	nucleoside	triphosphates	(5.13a-d,	and	5.19,	and	5.25a-d,	and	5.31)	in	figure	5.1	to	5.10	was	monitored	 by	 analytical	 HPLC	 chromatography	 with	 the	 gradient	 from	 0%	 to	 50	 %	 of	acetonitrile	 in	 0.1	M	 triethylammonium	 acetate	 buffer	 pH	 7.0	 over	 forty	minutes.	 Purity	determination	of	synthesized	5’-dNTPs	(5.13a-d)	was	monitored	by	the	co-injection	with	the	commercial	5’-	dNTPs	purchased	from	Sigma-Aldrich	by	analytical	HPLC	chromatography	in	figure	 S11	 to	 S14	 with	 the	 gradient	 from	 0%	 to	 10	 %	 of	 acetonitrile	 in	 0.1	 M	triethylammonium	acetate	buffer	pH	7.0	over	forty	minutes	of	analytical	run.		
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	The	research	accomplishments	presented	in	this	thesis	have	described	optimal	synthetic	strategies	 for	 α-L-threofuranosyl	 (TNA)	 monomers,	 nucleoside	 phosphoramdites,	 and	nucleoside	 triphosphates	synthesis	with	high	scalability.	Those	molecular	building	blocks	are	 used	 as	 immediate	 substrates	 to	 construct	 the	 TNA	 oligonucleotides	 chemically	 or	enzymatically	 for	 functional	 property	 evaluation	 and	 therapeutic	 application	 toward	 the	selected	biological	targets.		Here	we	have	developed	a	ten-step	synthetic	strategy	for	the	synthesis	of	TNA	nucleoside	monomers	and	phosphoramidites	in	quantitative	scale.	Key	challenges	have	been		resolved	and	purification	steps	were	minimized	 to	 increase	 the	yield	of	product	synthesis.	Several	TNA	nucleoside	intermediates	were	also	prepared	to	be	used	as	the	immediate	precursors	for	the	following	modified	TNA	nucleoside	and	nucleotide	synthesis.			Then	a	stepwise	synthetic	strategy	was	developed	to	construct	the	α-L-threofuranosyl	nucleoside	 monophosphates	 and	 nucleoside	 triphosphates.	 This	 method	 overcame	 the	challenge	of	poor	phosphorylation	efficiency	on	3’-OH	of	TNA	nucleoside	by	introducing	the	combined	 phosphitylation-oxidation	 reaction.	 The	 resulting	 TNA	 nucleoside	monophosphate	 precursors	 were	 subjected	 to	 a	 silica	 gel	 chromatography	 and	hydrogenation	reaction	to	generated	high	purity	of	TNA	nucleoside	monophosphates	that	preclude	 the	 HPLC	 purification.	 Then	 the	 stepwise	 high	 yield	 conversion	 from	 α-L-
185		
threofuranosyl	nucleoside	3’-monophosphates	to	nucleoside	3’-monophosphate	derivatives	to	nucleoside	3’-triphosphates	 facilitated	a	 throughput	HPLC	chromatography	of	 the	 final	products.	 This	 synthetic	 strategy	 was	 extensively	 applied	 to	 the	 2’-deoxy	 TNA	 nucleoside	triphosphates	 (Chapter	 4),	 and	 7-deaza-7-phenyl	 TNA-Guanosine	 nucleoside	 triphosphate,	Fluorescence	 activated	 tricyclic	 TNA-cytosine	 nucleoside	 triphosphate	 and	 several	 modified	TNA-Uracil	nucleoside	triphosphates	synthesis.		We	used	this	idea	for	the	chemical	synthesis	of	2′-deoxy-α-L-threofuranosyl	nucleoside	3′-triphosphates	 (dtNTPs).	 The	 key	 synthetic	 challenge	 was	 resolved	 by	 introducing	 the	triethylborane	as	the	radical	initiator	for	room	temperature	2’-deoxygenation	reaction	of	TNA	nucleosides.	Stepwise	phosphorylation	strategy	developed	in	chapter	4	allows	the	synthesis	of	2′-deoxy-α-L-threofuranosyl	nucleoside	3′-triphosphates	bearing	all	four	genetic	bases.	Looking	into	 future,	we	 suggested	 these	molecules	 can	be	used	as	 the	 chain	 terminators	 to	 study	 the	mechanism	of	TNA	synthesis	by	a	TNA	polymerase.	The	information	gained	from	this	studies	will	allow	 us	 to	 engineer	 the	 polymerase	 variants	 with	 better	 efficiency	 and	 faithful	 genetic	information	delivery.		Finally,	we	developed	 	a	novel	pyrophosphate	reagent	and	described	a	 fundamentally	different	 approach	 to	 generate	 triphosphate	 derivatives	 that	 are	 purified	 by	 silica	 gel	chromatography	and	converted	to	the	desired	compounds	on	scales	vastly	exceeding	those	achievable	by	HPLC.	The	power	of	this	approach	is	demonstrated	through	the	synthesis	of	a	broad	range	of	natural	and	unnatural	nucleoside	triphosphates	(dNTPs	and	xNTPs)	using	protocols	that	are	efficient,	inexpensive,	and	operationally	straightforward.		
186		





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PO HO 1 H		NM
R	spect
rum	of
	compo
und	5.1
8	
(500	M
Hz,D 2O
)	
5.
17
 
379		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.1
8	
(500	M
Hz,D 2O
)	
O
O
Bz
O
N
NH
O
O
4.
18
PO
O
HO
S
O
O
O
PO
O
HO
PO HO
5.
18
 
380		
																								
O
O
HO
N
NH
O
O
4.
19
PO
O
HO
PO
O
HO
PO HO
HO
1 H		NM
R	spect
rum	of
	compo
und	5.1
9	
(500	M
Hz,D 2O
)	
5.
19
 
381		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.1
9	
(500	M
Hz,D 2O
)	
O
O
HO
N
NH
O
O
4.
19
PO
O
HO
PO
O
HO
PO HO
HO
5.
19
 
382		
																								
O
N
NH
O
O
4.
22
a
PO
HO
HO
OB
z
O
1 H		NM
R	spect
rum	of
	compo
und	5.2
2a
	(500	M
Hz,CD 3
OD)	
5.
22
a 
383		
																								
O
N
NH
O
O
4.
22
a
PO
HO
HO
OB
z
O
13 C		NM
R	spect
rum	of
	compo
und	5.2
2a
	(500	M
Hz,CD 3
OD)	
5.
22
a 
384		
																							
31 P		NM
R	spect
rum	of
	compo
und	5.2
2a
	(500	M
Hz,CD 3
OD)	
O
N
NH
O
O
4.
22
a
PO
HO
HO
OB
z
O 5.2
2a
 
385		
																							
31 P		NM
R	spect
rum	of
	compo
und	5.2
3a
	(500	M
Hz,CD 3
OD)	
O
N
NH
O
O
4.
23
a
PO
N
HO
OB
z
O
N
5.
23
a 
386		
																								
1 H		NM
R	spect
rum	of
	compo
und	5.2
4a
	(500	M
Hz,D 2O
)	
PO
O
HO
S
O
O
O
PO
O
HO
PO HO
O
N
NH
O
O
4.
24
aO
Bz
O 5.2
4a
 
387		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.2
4a
	(500	M
Hz,D 2O
)	
PO
O
HO
S
O
O
O
PO
O
HO
PO HO
O
N
NH
O
O
4.
24
aO
Bz
O 5.2
4a
 
388		
																								
1 H		NM
R	spect
rum	of
	compo
und	5.2
5a
	(500	M
Hz,D 2O
)	
PO
O
HO
HO
PO
O
HO
PO HO
O
N
NH
O
O
4.
25
aOH
O 5.
25
a 
389		
																								
PO
O
HO
HO
PO
O
HO
PO HO
O
N
NH
O
O
4.
25
aOH
O 31 P		NM
R	spect
rum	of
	compo
und	5.2
5a
	(500	M
Hz,D 2O
)	
5.
25
a 
390		
																								
1 H		NM
R	spect
rum	of
	compo
und	5.2
2b
	(500	M
Hz,D 2O
)	
O
N
N
O
4.
22
b
PO
HO
HO
OB
z
O
NH
Bz
5.
22
b 
391		
																								
O
N
N
O
4.
22
b
PO
HO
HO
OB
z
O
NH
Bz
13 C		NM
R	spect
rum	of
	compo
und	5.2
2b
	(500	M
Hz,D 2O
)	
5.
22
b 
392		
																							
31 P		NM
R	spect
rum	of
	compo
und	4.2
2b
	(500	M
Hz,D 2O
)	
O
N
N
O
4.
22
b
PO
HO
HO
OB
z
O
NH
Bz
5.
22
b 
393		
																							
31 P		NM
R	spect
rum	of
	compo
und	5.2
3b
	(500	M
Hz,D 2O
)	
O
N
N
NH
Bz
O
4.
23
b
PO
N
HO
OB
z
O
N
5.
23
b 
394		
																								
1 H		NM
R	spect
rum	of
	compo
und	5.2
4b
	(500	M
Hz,D 2O
)	
PO
O
HO
S
O
O
O
PO
O
HO
PO HO
O
N
N
NH
Bz
O
4.
24
bO
Bz
O
5.
24
b 
395		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.2
4b
	(500	M
Hz,D 2O
)	
PO
O
HO
S
O
O
O
PO
O
HO
PO HO
O
N
N
NH
Bz
O
4.
24
bO
Bz
O
5.
24
b 
396		
																								
1 H		NM
R	spect
rum	of
	compo
und	5.2
5b
	(500	M
Hz,D 2O
)	
PO
O
HO
HO
PO
O
HO
PO HO
O
N
N
NH
Bz
O
4.
25
bOH
O 5.2
5b
 
397		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.2
5b
	(500	M
Hz,D 2O
)	
PO
O
HO
HO
PO
O
HO
PO HO
O
N
N
NH
Bz
O
4.
25
bOH
O 5.2
5b
 
398		
																								
1 H		NM
R	spect
rum	of
	compo
und	5.2
2c
	(500	M
Hz,CD 3
OD)	
O
N
4.
22
c
PO
HO
HO
OB
z
O
N
N
N
NH
Bz
5.
22
c 
399		
																								
13 C		NM
R	spect
rum	of
	compo
und	5.2
2c
	(500	M
Hz,CD 3
OD)	
O
N
4.
22
c
PO
HO
HO
OB
z
O
N
N
N
NH
Bz
5.
22
c 
400		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.2
2c
	(500	M
Hz,CD 3
OD)	
O
N
4.
22
c
PO
HO
HO
OB
z
O
N
N
N
NH
Bz
5.
22
c 
401		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.2
3c
	(500	M
Hz,CD 3
OD)	
O
N
4.
23
c
PO
N
HO
OB
z
O
N
N
N
N
NH
Bz
5.
23
c 
402		
																								
1 H		NM
R	spect
rum	of
	compo
und	5.2
4c
	(500	M
Hz,D 2O
)	
PO
O
HO
S
O
O
O
PO
O
HO
PO HO
O
N
4.
24
cO
Bz
O
N
N
N
NH
Bz
5.
24
c 
403		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.2
4c
	(500	M
Hz,D 2O
)	
PO
O
HO
S
O
O
O
PO
O
HO
PO HO
O
N
4.
24
cO
Bz
O
N
N
N
NH
Bz
5.
24
c 
404		
																								
1 H		NM
R	spect
rum	of
	compo
und	4.2
5c
	(500	M
Hz,D 2O
)	
PO
O
HO
HO
PO
O
HO
PO HO
O
N
4.
25
cO
H
O
N
N
N
NH
Bz
5.
25
c 
405		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.2
5c
	(500	M
Hz,D 2O
)	
PO
O
HO
HO
PO
O
HO
PO HO
O
N
4.
25
cO
H
O
N
N
N
NH
Bz
5.
25
c 
406		
																								
1 H		NM
R	spect
rum	of
	compo
und	5.2
2d
	(500	M
Hz,CD 3
OD)	
O
N
4.
22
d
PO
HO
HO
OB
z
O
N
N
NH
O
NH
Ac
5.
22
d 
407		
																								
13 C		NM
R	spect
rum	of
	compo
und	5.2
2d
	(500	M
Hz,CD 3
OD)	
O
N
4.
22
d
PO
HO
HO
OB
z
O
N
N
NH
O
NH
Ac
5.
22
d 
408		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.2
2d
	(500	M
Hz,CD 3
OD)	
O
N
4.
22
d
PO
HO
HO
OB
z
O
N
N
NH
O
NH
Ac
5.
22
d 
409		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.2
3d
	(500	M
Hz,CD 3
OD)	
O
N
4.
23
d
PO
N
HO
OB
z
O
N
N
N
NH
O
NH
Ac
5.
23
d 
410		
																								
1 H		NM
R	spect
rum	of
	compo
und	5.2
4d
	(500	M
Hz,D 2O
)	
PO
O
HO
S
O
O
O
PO
O
HO
PO HO
O
N
4.
24
dO
Bz
O
N
N
NH
O
NH
Ac
5.
24
d 
411		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.2
4d
	(500	M
Hz,D 2O
)	
PO
O
HO
S
O
O
O
PO
O
HO
PO HO
O
N
4.
24
dO
Bz
O
N
N
NH
O
NH
Ac
5.
24
d 
412		
																								
1 H		NM
R	spect
rum	of
	compo
und	5.2
5d
	(500	M
Hz,D 2O
)	
PO
O
HO
HO
PO
O
HO
PO HO
O
N
4.
25
dOH
O
N
N
NH
O
NH
2
5.
25
d 
413		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.2
5d
	(500	M
Hz,D 2O
)	
PO
O
HO
HO
PO
O
HO
PO HO
O
N
4.
25
dOH
O
N
N
NH
O
NH
2
5.
25
d 
414		
																								 O 4.27
OB
z
N
O
HN
O
O
PO OB
nOB
n
1 H		NM
R	spect
rum	of
	compo
und	4.2
7	
(500	M
Hz,CDC
l 3)	
5.
27
 
415		
																								
13 C		NM
R	spect
rum	of
	compo
und	5.2
7	
(500	M
Hz,CDC
l 3)	
O
4.
27
OB
z
N
O
HN
O
O
PO OB
nOB
n
5.
27
 
416		
																								
31 P		NM
R	spect
rum	of
	compo
und	4.2
7	
(500	M
Hz,CDC
l 3)	
O
4.
27
OB
z
N
O
HN
O
O
PO OB
nOB
n
5.
27
 
417		
																								
1 H		NM
R	spect
rum	of
	compo
und	5.2
8	
(500	M
Hz,CD 3
OD)	
O
4.
28
OB
z
N
O
HN
O
O
PO OH
OH
5.
28
 
418		
																								
13 C		NM
R	spect
rum	of
	compo
und	5.2
8	
(500	M
Hz,CD 3
OD)	
O
4.
28
OB
z
N
O
HN
O
O
PO OH
OH
5.
28
 
419		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.2
8	
(500	M
Hz,CD 3
OD)	
O
4.
28
OB
z
N
O
HN
O
O
PO OH
OH
5.
28
 
420		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.2
9	
(500	M
Hz,D 2O
)	
O
4.
29
OB
z
N
O
HN
O
O
PO OH
N
N
5.
29
 
421		
																								
O
4.
30
OB
z
N
O
HN
O
O
PO OH
O
PO
O
OH
PO
O
OH
SO O
1 H		NM
R	spect
rum	of
	compo
und	5.3
0	
(500	M
Hz,D 2O
)	
5.
30
 
422		
																							
O
4.
30
OB
z
N
O
HN
O
O
PO OH
O
PO
O
OH
PO
O
OH
SO O
31 P		NM
R	spect
rum	of
	compo
und	5.3
0	
(500	M
Hz,D 2O
)	
5.
30
 
423		
																								
1 H		NM
R	spect
rum	of
	compo
und	5.3
1	
(500	M
Hz,D 2O
)	
O
OH
N
O
HN
O
O
PO OH
O
PO
O
OH
PO
OH
OH
4.
31 5.
31
 
424		
																								
31 P		NM
R	spect
rum	of
	compo
und	5.3
1	
(500	M
Hz,D 2O
)	
O
OH
N
O
HN
O
O
PO OH
O
PO
O
OH
PO
OH
OH
4.
31
5.
31
 
425		
			 APPENDIX	B					 SUPPLEMENTAL	HPLC	CHROMATOGRAM																		
426		
																							
427		 	
428		
																							
3.
7a	
 
4.7a	
4.7b	
4.7c	
4.7d	
429		
	
4.9a	
4.9b	
4.9c	
4.9d	
430		
		
	
	
	
	
	
	
	
	
	
	
	
									
